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CHAPTER 1
Introduction:
Folate, a water-soluble B vitamin, has emerged as an important nutritional
element in the pathogenesis of several malignancies, including cancers of the
colorectum, lung, pancreas, esophagus, stomach, cervix, and breast, as well as
neuroblastoma and leukemia. Studies have collectively implied an inverse
association between dietary and serum folate and the risk of malignancy (1, 2).
The most convincing relates to colorectal cancer (3, 4).
Folate Digestion, Absorption and Metabolism
Folate is the naturally occurring form of the vitamin found in foods, which
have similar nutritional properties of folic acid (5, 6). The U.S. RDA for folate is
400 micrograms per day for nonpregnant ages 19 to 50 years. Folic acid (aka
pteroylmonoglutamic acid), is rarely found in natural food items but is the source
used in the fortification of foods and supplements (7). Dietary folate is only about
50% bioavailable (8), whereas folic acid is 85% bioavailable (9). Bioavailablity is
dependent on the length of the polyglutamate chain to which most of the natural
folate is attached. Digestion of folates begins in the small intestine. Initially,
folylpoly-glutamate carboxypeptidase, a brush border enzyme, removes dietary
folate polyglutamates up to their corresponding monoglutamate derivatives, 5methyltetrahydrofolic acid and 5-formyltetrahydrofolic acid, through removal of
glutamate residues. These monoglutamates, which now carry a reduced negative
charge, are subsequently actively absorbed, mainly in the jejunum, via the
reduced folate carrier (RFC) or the protein-coupled folate transporter and
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converted to tetrahydrofolic acid (THF) by dihyrofolate reductase (DHFR), an

NADPH-requiring enzyme. THF is subsequently converted to 5-methyl-THF and
then transferred to the portal circulation which are taken up by the liver or
converted to 5-methyl-THF, before entering the plasma. From the plasma,
specific carriers (RFC) or receptors (folate receptors α or β) transport 5-methyl-

THF into cells. 5-methyl-THF undergoes polyglutamation altering the properties
of the molecule such that transportion through the membrane is inhibited and
causing an accumulation in the liver and cells. Enzymes involved in folate
metabolism have a higher affinity for polyglutamate forms of folate. Many of the
inter-conversions of folates are oxidation-reduction reactions that utilize NADH,
NADPH and ATP. It should be noted that folates may also be absorbed through
the colon due to microbial folate production. Here the absorption rate is
estimated to be ~50 times lower than in the small intestine; however, it may
contribute significantly to total folate absorption (10).
Folate in one carbon metabolism
Folate has an essential role as a one carbon donor in DNA metabolism

(Fig. 1) (11). It functions as a methyl donor through 5-methyltetrahydrofolate,
remethylating homocysteine to methionine, which in turn is converted to Sadenosylmethionine (SAM), the primary intracellular methyl donor.
Subsequently, SAM methylates specific cytosines in DNA and this regulates
gene transcription. In addition, folate through 5,10 methylene THF, donates a
methyl group to uracil (U) converting it to thymine, crucial for DNA synthesis and
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repair (12). 5,10 methylene THF can be oxidized to form 10-formyl-THF for
denovo synthesis of purines (13, 14).

Figure 1.1
Folate and disease
Since the installation of folate fortification of cereal grains by the Food and
Drug Administration, to eradicate NTDs, median RBC folate levels of women of
childbearing age increased 65%, from 160 ng/mL to 264 ng/mL between 1988
to1994 and 1999 to 2000. The NHANES 2005 to 2006 value is 257 ng/mL. In
addition, the prevalence of low RBC folate among U.S. women of childbearing
age declined from 37.6% in 1988 to 1994 to 5.1% in 1999 to 2000. The 2005 to
2006 value was 4.5% (15). Honein et al. (2001)(16), report a 19% reduction in

NTD birth prevalence following folic acid fortification of the US food supply.
Despite this massive effort, however, there remains a high incidence of diseases
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like CVD, stroke, Alzheimer’s disease, depression and cancer. It is suggested
that these disease states continue to prevail potentially as a result of genetic
disorders of enzymes involved in folate metabolism, increasing age, and alcohol
useage.
Aberrations in folate metabolism include polymorphisms in a number of
essential genes related to this pathway. One example is that of the RFC, as
previously described, whose variations can give rise to a variety of cancers (17,
18 and 19). As well, mutations in the Folate receptor-alpha (FR-alpha) gene
which binds and transports folates, namely 5-methylTHF, into cells have been
documented.

Polymorphisms

in

this

gene

are

said

to

contribute

to

hyperhomocysteinemia (20) increasing the risk of disease.
Methylenetetrahydrofolate reductase (MTHFR) is an enzyme responsible for the
conversion of 5,10-methyleneTHF to 5-methylTHF, a cosubstrate for the
remethylation of homocysteine to methionine. Two well studied polymorphisms
of this gene include MTHFR C677T, which is a C→T variation at nucleotide 677
(C677T), as a results of alanine to valine substitution in the MTHFR protein and
MTHFR

A1298C

(A→C;

glutamic

acid

substitution

to

alanine).

Both

polymorphisms lead to reduced MTHFR activity, resulting in the accumulation of
5,10-methylene THF and a decrease of 5-methyl THF (21) contributing to

hyperhomocysteinemia.

Other

genetic

variations

include

serine

hydroxymethyltransferase (SHMT) (C→T substitution), which catalyzes the
reversible conversion of serine and THF to glycine and methylene THF, thus
providing one carbon units for synthesis of methionine, thymidylate and purine in
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the cytoplasm, and methionine synthase (MS, A→G substitution) which catalyzes
the transfer of methyl base from 5-methyl THF to homocysteine, producing
methionine and tetrahydrofolate. The aforementioned is critical for maintenanace
of SAM levels for DNA methylation and safeguarding of homocysteine levels.
SHMT polymorphisms have been observed in ovarian (22), lung (23) and
squamous cell carcinoma of the head and neck (24). Additionally polymorphisms
are seen in variable number tandem repeats (VNTRs) for thymidylate synthase
which catalyzes the conversion of dUMP to dTMP and thus plays a critical role in
maintaining a balanced supply of deoxynucleotides required for DNA synthesis.
Aging has profound effects on 1-carbon metabolism, discernible by
hyperhomocysteinemia, genomic DNA hypomethylation, and impact on DNA
repair systems. Achlorhydria, which is a lack of hydrochloric acid in digestive
juices, is a common physiological change that occurs with aging (25). A pH < 7 is
required for optimal absorption of folate monoglutamate (26), as such,
achlorhydria can result in reduced folic acid absorption and folate depletion (25,
27). Ethanol associated folate deficiency can develop because of poor dietary
practices, intestinal malabsorption, altered hepatobiliary metabolism, enhanced
colonic metabolism, and increased renal excretion of folate secondary to alcohol
consumption. Ethanol reduces the intestinal and renal uptake of folate by
changing the binding and transport kinetics of folate transport systems. Also,
ethanol may lead to a folate deficiency as a result of reduced expression of folate
transporters in both intestine and kidney contributing to folate malabsorption (28).
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Folate Deficiency and Cancer
Over the last several decades’ research studies have indicated an
inverse association of low dietary folate intake and the development of certain
cancers such as those of the esophagus, stomach, breast, leukemia, pancreas
and others with the evidence most compelling for colon cancer. Larsson et
al.(29), conducted a meta-analysis for studies published through March 2006
which supported low dietary folate intake with increased risk of esophageal
squamous cell carcinoma, esophageal adenocarcinoma and pancreas, cancers
that were 40%–50% less likely to develop when dietary folate intake was high.
Most, although not all, showed an increased risk of these cancers with the

MTHFR 677TT genotype, which disrupts folate metabolism. Others have shown,
in mucosal tissue samples from patients with gastric cancer, a lower folate
concentration, detected by the FOL ACS:180 automated chemiluminescence
system, then in controls (30). Likewise, Gao et al. (31) observed a significant
inverse relationship in 669 breast cancer cases between folate intake and breast
cancer risk. Of interest, Giovanucci et al. (32), in their study of 88 756 women
from the Nurses' Health Study showed a reduced risk of development of colon
cancer with long term high folate intake. In addition, animal studies have
demonstrated time constraint for folate supplementation with initiation prior to the
establishment of neoplastic foci essential for suppression of development and
progression of cancer. If supplementation coincides with preexisting foci
formation, this B-vitamin can enhance the growth of these preneoplastic lesions
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(33, 34 and 35). Lindzon et al. (2009)(36) in their male Sprague-Dawley rats
showed an increase in progression of colonic preneoplastic lesions to colon
tumors when folic acid was supplemented six weeks post-ACF induction.
It is believed that the mechanism of folates protection may be a result of
the maintenance of normal DNA synthesis and DNA methylation (37). If folate is
deficient, 5-methylTHF will not be sufficient to provide the methyl group to
methylate homocysteine to methionine, SAM will become depleted. This would
give rise to abnormal metabolism of methyl groups which impacts DNA
methylation, a cellular process that may be detrimental in neoplastic
transformation (38). Atypical methylation of cytosine residues of cytosine-guanine
dinucleotide pairs impacts epigenetic gene expression and also has a role in
maintaining DNA stability. Hypermethylation of promoter regions has the ability to
silence tumor suppressor genes, which inhibit uncontrolled cell growth that could
lead to the formation of tumors. In contrast, global hypomethylation of
protoncogenes may cause their overexpression, a root for the transformation of
normal cells into cancer cells via chromosomal instability and increase mutational
frequency (39). As well, if cellular folate becomes deficient DNA stability may be
reduced by a disruption in the nucleotide pool, negatively altering DNA synthesis
and repair. Reduced synthesis of thymidylate from the imbalances in the
deoxyribonucleotide pool results in massive uracil misincorporation into the DNA,
leading to “a catastrophic repair cycle”. This may lead to DNA strand breaks,
deletions,

chromosomal

breaks,

micronucleus

formation

and

heterozygosity (40, 41, 41). In contrast, folate supplementation after

loss

of
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development of preneoplastic lesions maybe attributed to folate's tumor
promoting effect (43). Cancer cells are cells that are categorized as having rapid
levels of DNA replication and cell division occurring. Folate once again is the
cofactor in the synthesis of nucleic acids and is required for DNA repair, which
would only facilitate the growth of preneoplastic cells. If one considers the basis
of use of antifolates in the treatment of certain cancers, it would only seem
practical to recognize that a reduction of folate would cause inhibition of tumor
growth.
The

Base

Excision

Repair

Pathway

(BER)

BER is the predominant pathway in mammalian cells for repair of small DNA
base lesions and abasic sites which arise spontaneously as a result of alkylation,
oxidation and deamination events (44, 45, 46). It is estimated that BER is
responsible for the repair of as many as one million nucleotides per cell per day
(47). In general, the BER pathway involves the following steps: i) DNA
glycosylase enzymes remove damaged nucleic acid bases (purines or
pyrimidines), ii) Endonuclease enzyme cleaves the phosphodiester backbone, iii)
synthesis of new DNA by a DNA polymerase using the complementary strand as
a template, iv) excision of the 5’-deoxyribose phosphate (dRp) terminus, v)
recreation of the phosphodiester bond by a ligase (48). Two subpathways of BER
have been recognized: ‘short patch’ which is responsible for the replacement of a
damaged base with a single new nucleotide, and the ‘long patch’ which results in
the replacement of approximately 2-10 nucleotides
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Mechanisms of Base Excision Repair Pathway
Major Pathway

Monofunctional
Bifunctional

DNA Glycosylase

DNA Glycosylase
3’- β-lyase
Unmodified
AP-sites

Minor Pathway

O
APE

Reduced or Oxidized
AP-sites

β-pol, ε, δ

FEN-1
PCNA

3’-end “trimming”
By APE / β-pol

β-pol

β-pol
XRCC1

β-pol
XRCC1
XRCC1

FEN-1
PCNA

LIG 1

LIG3α

Figure 1.2

including the damaged base (49). The ‘short patch repair pathway is the
dominant pathway representing approximately 75-90% of all BER (50).
‘Short-patch’ base excision repair:

The short-patch repair pathway is a

DNA polymerase ß-dependent pathway (51). There are two types of
glycosylases, monofunctional and bifunctional. In monofunctional glycosylaseinitiated BER, a damaged or improper base is recognized and removed by
enzymatic hydrolysis of the N-glycosyl bond creating an AP site. This AP site
serves as a substrate for the endonuclease APE, which nicks the backbone
directly 5’ of the AP site, creating a single strand break with a normal 3’-hydroxyl
group and an abnormal 5’dRP terminus. β -pol then inserts a new base followed
by the excision of the of the abnormal 5’dRP (52). This latter step has proven to
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be rate limiting (53). In bifunctional glycosylase initiated BER, a DNA specific
glycosylase recognizes the damaged base, excises it and makes an incision in
the backbone with its associated AP lyase activity, yielding a normal 5'-terminal
deoxynucleoside-5'-phosphate residue and an abnormal 3'-terminal α,βunsaturated aldehyde residue that must be processed prior to completion (53).
By virtue of its 3’phosphodiesterase activity, Ape 1 performs this rate-limiting step
that excises the deoxyribose fragments and phosphate groups at the 3’ terminus
of DNA (54). Completion of BER requires seal of the nicked phosphodiester
bond, the majority of which is completed by a complex of XRCC1 and DNA ligase
III (55).
‘Long-patch’ base excision repair: If damage is refractory to dRP moiety
excision, then ‘long patch’ BER completes the repair. In this pathway, DNA
polymerase β or e adds a few more nucleotides to the 3’-end of the nicked AP
site (56) creating a flap that is removed by a flap endonuclease (FEN1) (57). The
DNA ends are subsequently sealed by DNA ligase I (58). It has been shown that
cells insufficient in β -pol were deficient in ‘short-patch’ BER, but proficient in

‘long-patch’ BER. This suggests thatβ -pol is the polymerase in the ‘short-patch’
BER, whereas DNA polymerase β or ε are the main polymerases of the ‘longpatch’ BER pathway (59).
The BER deficient mouse model
Based on β-pol role in the BER pathway on removal of uracil, alkylated
and oxidized bases we decided to utilize the β-pol haploinsufficient mouse model
to study the effects of folate deficiency in colon carcinogenesis. While
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homozygous deletion of the β-pol gene in the mouse germ line results in lethality,
+/-

β-pol

heterozygote transgenic mice appears normal and fertile.
+/-

previously characterized the β-pol

We have

mice as having a 40 to 50% reduction in

mRNA β-pol levels and a 50 to 60% decrease in β-pol protein levels.
Additionally, we have shown an increased accumulation of SSBs and
chromosomal aberrations that occur spontaneously in this animal model relative
to their WT littermates. These incidences are exacerbated with the inclusion of
oxidizing and alkylating agents and in addition demonstrate an increase in
mutational frequency (60). These happenings proved similar to the DNA damage
that is induced in folate deficiency making it plausible to further study the
connection between this repair pathway and folate.
Polymerase β is indispensible in ‘short patch’ repair for both its lyase and
gap filling. It appears that β-pol also has a role in ‘long patch’ repair by the
insertion of several nucleotides (61). Examples of base lesions repaired by BER
pathway include oxidized bases such as 8-oxoguanine, 2,6-diamino-4-hydroxy-5formamidopyrimidine, alkylated bases like 3-methyladenine, 7-methylguanine,
deaminated bases like hypoxanthine that arise from the deamination of adenine or
uracil formed by deamination of 5-methylcytosine or its misincorporated in DNA.
Although the ‘short patch’ repair pathway is the dominant pathway representing
approximately 75-90% of all BER (50), β-pol has an important role in both BER
pathways. Accordingly, removal of β-pol would be reasonable to study the BER
deficient model. We have previously (62) shown that WT animals exposed to
oxidative damage had increased BER and β-pol levels, whereas, β-
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pol haploinsufficient mice, as previously mentioned, exhibited a greater
occurrence of SSB than WT (60).
ββ-pol

+/-

Mice as a Model for BER Polymorphisms

β-pol is a monomeric polypeptide of 335 amino acids consisting of two
domains: an 8-kDa amino-terminal lyase domain and a 31-kDa active site
carboxy-terminal polymerase domain (63, 64). The amino-terminal domain is
involved in binding to single stranded DNA, recognition of the 5’-phosphate in
gapped DNA, removal of the 5’-dRP group from AP endonuclease-incised DNA,
and AP-site strand incision (65). The carboxy-terminal domain binds weakly to
double stranded DNA and possess nucleotidyltransferase activity (63, 66). β-pol
is located on the proximal region of the short arm of chromosome 8 (p12-p11)
(67).
+/-

The Heydari lab has previously shown that β-pol

results in genomic

instability (68). The β-pol haploinsufficient mouse has a reduced ability to tolerate
carcinogen exposure, demonstrating reduced BER capacity and this translates
into concern regarding the development of certain cancers. In fact,
mutations in the gene encoding β-pol have been previously identified in human
colorectal, prostate, lung and breast carcinomas (69, 70, 71, 72). These
mutations are found only in the tumor tissue and not in the adjacent normal
tissue, thus corresponding to sporadic mutations (73).
Studies have shown that approximately 30%of human tumors are
characterized by mutations in β-pol including those of the colon, prostate, lung,
breast and bladder (Starcevic et al, 2004). In particular those of the colon include
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a β-pol single nucleotide polymorphism (SNP) where positively charged Lys-289
was substituted for a neutral Met (K289M). This variant leads to altered
positioning of DNA within the K289M enzyme leading to misincorporation of
nucleotides (74) during BER, lowering its fidelity. In Lang’s study they utilized cII
mutants from cells expressing K289M showing an increased frequency of C to G
base substitutions within the AACAAA sequence. This polymorphism observed
resembles the mutational hotspot within the APC gene, a gene that is frequently
mutated in colon carcinoma. Wang et al. (75), observed this alteration in human
colorectal carcinomas, a mutation found only in the tumor tissue and not in
normal, surrounding mucosa (74). These abovementioned findings indicate that
this variant could impact the cell through haploinsufficiency and modify risk for
colon cancer. This SNP, along with others found in various tissues (I260M
prostate carcinoma and E295K gastric carcinoma, (76)), confer that the β-pol
haploinsufficient animal can serve as a model mimicking human polymorphisms.
We have previously shown that β-pol haploinsufficiency results in genomic
instability (60). Furthermore, β-pol haploinsufficient mice display an acceleration
of normal, age-related tumors, e.g., lymphomas, as well as increased
susceptibility to epithelial tumors, such as adenocarcinomas, phenomenon that
do not typically occur to a high degree in C57BL/6 mice (77). Consequently,
previous experimental work done in our lab and others strengthens the cause for
using a β- pol haploinsufficient mouse as a model to study CRC.

Folate deficiency and Base Excision Repair
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While uracil is not a normal constituent of DNA it can arise in DNA during
replication when dUMP:dTMP ratios are imbalanced. It may also arise as a result
of the deamination of cytosine which is the hydrolysis reaction of cytosine into
uracil. The frequency of cytosine deamination is elevated when SAM levels are
reduced (78), as seen in folate deficiency. The DNA repair pathway primarily
responsible for removal of uracil is the base excision repair (BER) pathway.
Misincorporation of uracil, as seen in folate deficiency (79), constitutes a
nucleotide that is normally repaired by the ‘short-patch’ BER pathway. Briefly, the
removal of uracil by BER involves i) uracil-DNA glycosylase (UDG) binding
specifically to the affected base and hydrolyzing the N-glycosidic bond, releasing
the damaged base while keeping the DNA backbone intact. ii) The abasic site is
subsequently recognized by an endonuclease, notably Ape 1, which nicks the
phosphodiester backbone immediately 5’ to the lesion leaving a strand break with
a normal 3’-hydroxyl group and an abnormal 5’dRp residue. iii) synthesis of new
DNA by incorporation of the correct nucleotide by DNA polymerase, iv) excision
of the 5’dRp moiety, and v) ligation by a DNA ligase (Ligase 1 or Ligase
3/XCRR1 (1).
Evidence from our lab, as well as others, demonstrate a reduced ability to
process DNA damage when folate deficiency is present. We have shown that
folate deficient mice display an initiation of BER, as observed by an increase in
uracil DNA glycosylase; however there is a stalling at the rate-limiting enzyme
DNA polymerase β. Consequently, we observed an accumulation of DNA single
strand breaks (80), which if left unrepaired could emerge as a DNA double strand
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break. Similarly, Blount et al.(81) using folate deficient human erythrocytes,
showed increased levels of uracil in DNA as well as, an increase in micronuclei
formation. In addition, Branda et al. (82) have demonstrated that folate deficient
Weanling Fischer 344 rats are less able to repair damages induced by alkylating
agents. Although they show that folate deficiency on its own was mutagenic, in
conjunction with ENU, an alkylating agent, it was found to be even more
mutagenic. Branda has also shown (83) that folate deficiency acts synergistically
with EMS in CHO cells to increase DNA strand breaks and mutant frequency.
Duthie and Hawdon (84) have shown that folate depletion in human lymphocytes
makes the cells more sensitive to oxidative damage induced by hydrogen
peroxide. Duthie et al. (85) have further shown that human colon epithelial cells
grown in the absence of folate are poorly able to repair damages induced by
MMS (an alkylating agent) and hydrogen peroxide (an oxidizing agent). Growth in
a low folate medium has also been shown to impair excision repair capacity of
colonocytes (86). More oxidative damage, which is repaired by BER,
accumulates in response to amyloid β-peptide in neuronal cells depleted of folate
(87). These data indicate that the pathway responsible for repairing these
damages may be ineffective when folate is limiting. These findings are rather
compelling for the effects of folate on cellular DNA appear to mimic those that are
seen when β-pol is deficient. We would suggest that this phenomenon occurs
conceivably by overwhelming the capacity of BER through inhibition of its rate
determining enzyme, DNA polymerase β. Specifically, we have previously shown
that with β-pol haploinsufficiency, there is a lack of induction of β-pol and
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an accumulation of SSB (60), much the same as perceived in folate deficiency

(80).
Colon Cancer
In the US, colorectal cancer is the second leading cause of cancer-related
death and accounts for approximately 25% of all cancer deaths in the Western
world. It is believed that 85% of CRC cases are caused by sporadic mutation,
that is, it occurs in people who have no (or very little) family history of the disease
and therefore is due to diverse environmental risk factors. The remaining CRC
cases are thought to be a result of genetic predisposition notably hereditary
nonpolyposis colorectal cancer (HNPCC) and familial adenomatosis polyposis
(FAP) (88). Sporadic Colon Cancer occurs in people who have no (or very little)
family history of the disease and generally occurs in individuals over age 50
years. It has been stated that inactivation of the APC gene is found in about 85%
and inactivation of the mismatch repair genes, including MSH2, MLH1, and
PMS2, is found in the remaining 15%of sporadic colon cancers (89). Hereditary
nonpolyposis colorectal cancer (HNPCC) is the more common form of hereditary
colon cancer. It is an autosomal dominantly inherited condition characterized by
an early onset of either colon, endometrial, ovarian, urinary tract, stomach, small
bowel, biliary tract, or brain cancers. The average age of diagnosis is 44 years
for colon cancer. It is estimated that 5 genes related to mismatch DNA repair are
responsible for the development of this disease (90). This condition gives rise to
a modest number of polyps in the colon beginning in the third or fourth decade of
life (90) and are described as highly villous and dysplastic with a rapid

17
progression to cancer (90, 91). FAP is an inherited condition that results from
defects in the adenomatous polyposis coli (APC) gene. APC is a known tumor
suppressor that prevents the uncontrolled growth of cells that may result in
cancerous tumors. If this gene develops a mutation, the protein made by APC
cannot suppress cellular overgrowth leading to the formation of polyps, which
can overtime become cancerous. Polyp formation begins in early adolescence
with the number and size increasing with time. The pathology of polyps in FAP is
indistinguishable from sporadic colon cancers; however, due to the vast number
and early development of polyps, most individuals with FAP will develop colon
cancer (90).
Progression of colon cancer is thought to occur over a period of many
years in a multistep process involving a series of pathological alterations ranging
from discrete microscopic mucosal lesions, like aberrant crypt foci (ACF), to
malignant tumors (92, 93). Subtle alterations in the regular pattern of ACF are
among the first histologically detectable changes that may be linked with
colorectal cancer development (CRC) (94, 95, 96). The growth, morphological
and molecular features of ACF supports the line of reasoning that ACF are
putative preneoplastic lesions (97). Bird (92) was the first to describe ACF in the
colonic mucosa of rodents exposed to colorectal carcinogens. These ACF which
have long been considered as preneoplastic lesions and precancerous lesions,
appear larger, with a thicker epithelial lining than adjacent normal crypts and
dilated irregular luminal openings rising above the surrounding mucosa. These
lesions have been observed as early as two weeks after administration of the
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colon carcinogen DMH (98). Evaluation of solitary crypts demonstrates the
aberrant crypts divide by fission beginning near the base of the crypt (99)
growing overtime to form a focus with multiple aberrant crypts (100). ACF in
humans closely resembles the aberrant crypts detected in rodents treated with
carcinogens (101). It should be noted that although the number of ACF increases
with increased exposure to carcinogens little evidence supports tumor
development with increasing numbers (102). In other words, aberrant crypts do
not indicate that colon cancer is imminent.
Base Excision Repair, Folate Deficiency and Colon Cancer
The association between BER, dietary folate and colon carcinogenesis is
probably linked to folate deficiencies role in the ‘catastrophic repair’ cycle that
arises due to extensive DNA damage secondary to decreased synthesis of both
thymidylate and purines. Under thymidylate duress, BER is inefficient in repair
due to the resynthesis step where elevated dUTP causes reintroduction of
genomic uracil. Uracil may arise in DNA, in small quantities as a result of
spontaneous cytosine deamination or/and misincorporation of dUMP during DNA
replication. Frederico et al. (103), using a genetic reversion assay conservatively
estimated that this occurs approximately 50 times per cell per day in the human
genome. With folate deficiency, however, the rate of cytosine deamination
increases as much as 10,000-fold (78). This rate would likely stress or overwhelm
the DNA repair pathway, leading to single strand breaks that if left unrepaired are
clastogenic (104). This can give rise to sections of the
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chromosome being deleted, added, or rearranged, hence the inception of
mutagenesis which can further develop to carcinogenesis.
Introduction of other DNA repair pathways
NHEJ is considered to be responsible for resolving DSBs that occur in the
G1 phase of the cell cycle, while HR is responsible for resolving DSBs during S
and G2 phases. NHEJ is an error prone pathway, whereas HR is quite accurate
(104). There have been reports of cross-talk between homologous recombination
(HR) and BER. It is said that HR responds to persistent BER strand break
intermediates (Wyatt et al., 2006) which would seem appropriate as SSB can
give rise to DSB if left unrepaired. The demand for deoxynucleotides required for
the resynthesis step of HR can extend up to thousands of nucleotides in
comparison to the 1 to 5 nucleotides required to complete BER, presenting a
problem with folate is deficient. Use of HR when nucleotide pools are imbalanced
would appear to be deleterious, nevertheless it may be the only way to recover
stalled and/or collapsed replication forks. Currently there is a lack of evidence for
a role of NHEJ in folate deficiency,
Folate Deficiency and mismatch repair
Mismatch repair is a system for recognizing and repairing of damage
incurred during DNA replication. Mutations in MMR genes results in microsatellite
instability (MSI) which is instability of repeated sequences of DNA. Research has
shown that MSI has a frequency of 10% to 20% in colon cancers which is
attributed to both MLH1 promoter hypermethylation and germline mutations in
MMR genes (MLH1, MSH2, MSH6, PMS1, and PMS2, (105, 106).
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Poynter et al. (106) have also shown that 54% of population-based MSI cases
had hMLH1 methylation. MSH2 and MSH6 detect DNA mismatches at which
point they recruit MLH1 and PMS1to the repair sites. MLH1 proteins join with
PMS2 to form the major complex for mismatch repair (107). This complex is
responsible for the coordination subsequent repair events. Folate deficiency has
also been observed to impair MMR, in nonneoplastic ulcerative colitis patients
(108). It was believed that a defect in MMR in these patients might translate into
an increased risk for mutations. Due to the fact that DNA methylation has a role
in strand discrimination during postreplication MMR, aberrations in normal
patterns of DNA methylation, which can occur with folate deficiency, might
adversely affect this DNA repair mechanism. Both DNA hypomethylation which
would impinge upon the methyl-directed MMR and methylation of CpG sites in
the hMLH1 gene, which has been associated with MSI in colon and stomach
cancer (109), can be induced by folate deficiency (110). Although BER and MMR
have both been proven to have a basis in colon carcinogenesis, the causes
are distinct defining the necessity to utilize β-pol-deficient animal model to
directly test an effect of BER.
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CHAPTER 2
Hypothesis and Specific Aims
Folate deficiency has been shown to result in low levels of nucleotide
synthesis and in addition elevated levels of uracil being misincorporated in to
DNA. Uracil incorporated into DNA is initially excised from DNA by uracil-DNA
glycosylase at which time apyrimidinic endonuclease creates a nick in the DNA
phosphate backbone. With massive uracil misincorporation as seen in folate
deficiency it appears to create a ‘futile’ repair cycle in that there is an
accumulation of transient single strand breaks that could result in a less
repairable and more harmful double-strand breaks if two opposing nicks are
formed. Accumulation of the aforementioned could result in chromosomal
aberrations, increased mutational frequency and potentially the onset and
progression of cancer, particular those of the colon. This scenario appears to be
aped when β-pol is haploinsufficient. The objective of this research was,
therefore, to elucidate the molecular mechanisms by which β-pol impacts colon
cancer when folate is deficient.
β-pol, being the rate limiting enzyme in the BER pathway, was expected to
result in significantly deleterious effects when folate was deficient. It was thought
that if β-pol were deficient, with the removal of uracil from the DNA by uracil-DNA
glycosylase and the generation of transient SSBs that occurs with folate
deficiency, this β-pol haploinsufficiency would create an extremely toxic level of
unrepaired BER intermediates that would progress to ACF development and
colon cancer progression. Thus, I tested the hypothesis that the accumulation of
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DNA damage, preneoplastic lesions and tumors in colon caused by folate

deficiency and carcinogen exposure will be accelerated by loss of β-pol. Using
heterozygous β-pol in which one allele was inactivated and wildtype C57bl mice,
I directly tested the impact of folate deficiency on BER activity in the β-pol
haploinsufficient mouse model when exposed to the colon carcinogen DMH.
Specific Aim 1:

To determine whether BER deficiency accelerates the

induction of ACFs induced by DMH when folate is deficient. That is, to test
whether the accumulation of damages seen in folate deficiency results in the
acceleration in onset and progression of precancerous lesions when β-pol is
deficient. The accumulation of uracil,
abasic sites and DNA single strand breaks can translate into toxic repair
intermediates that create DNA damage in the form mutations when folate is
deficient. I predicted that folate deficiency would increase the accumulation of
+/-

DNA damage and mutational frequency in the β-pol

mice to a greater extent

than it would in the wildtype mice due to the deficiency in base excision repair
capacity. Both β-pol haploinsufficiency and folate deficiency on their own are
genotoxic so it seemed only rational to assume that when combined the effects
would be magnified with profound DNA damage and mutations and in contrast,
the folate supplemented wildtype mice would prove resistant even after treatment
with a colon carcinogen. This in turn would demonstrate that a folate deficit would
further impair an already deficient BER pathway when β-pol is haploinsufficient.
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Specific Aim 2: To determine whether ββ-pol haploinsufficiency in a folate
deficient environment accelerates the induction of tumors caused by DMH

when folate is deficient. As stated previously, ACF development does not imply
that colon cancer is forthcoming. in fact, a majority regress, however, it is wellestablished that an accumulation of DNA damage, mutations, or chromosomal
abnormalities are initiating events in the genesis of cancer. Our


previous studies have determined an increase in tumor development in β-pol mice.
So this study aimed to determine if the combined effect of β-pol haploinsufficiency
and folate deficiency would induce higher levels of ACF and if these putative
markers were more likely to progress to neoplastic lesions. That
is I depicted that folate deficiency imposed in a BER deficient environment would
result in a more advanced ACF where they had increased proliferative capacity
and reduction of cell death secondary to the mutational effects of lack of repair by
β-pol haploinsufficiency. It seemed plausible to assume that the transformation in
the DNA from this stressful environment would result in increased cell number
(hyperplasia) progressing ACF to neoplastic lesions.
Specific Aim 3:

To determine the impact of ββ-pol

+/-

on gene expression

when folate was deficient. Looking at gene expression analysis would help to
elucidate the molecular mechanisms by which β-pol heterozygosity would
influence ACF formation and colon tumorogenesis. Changes in expression of key
genes could depict a more global indication of cellular mechanistic changes due
to effects of β-pol heterozygosity in an environment deficient in folate. From this
data we could not only elucidate changes in gene function but as well it may
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highlight changes in key cellular pathways of colon carcinogenesis, such as cell
cycle, apoptosis and colon carcinogenesis.
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CHAPTER 3
Folate deficiency provides protection against colon carcinogenesis in DNA
polymerase ββ haploinsufficient mice.
1

1

1

Lisa Ventrella Lucente , Archana Unnikrishnan , Amanda B. Pilling , Hiral V.
1

1

Patel ,

2

3

Deepa Kushwaha , Alan Dombkowski , E.M. Schmelz , Diane C.
1

1

Cabelof , Ahmad R. Heydari .
1

Department of Nutrition and Food Science, Wayne State University, Detroit, MI,

United States.

2

Institute of Environmental Health Sciences, Wayne State
3

University, Detroit, MI, United States. Department of Human Nutrition, Foods
and Exercise, Virginia Tech, Blacksburg, VA, USA.
Running Title: Folate deficiency, β-pol and Colon Carcinogenesis
Reprint Requests: Ahmad R. Heydari, Department of Nutrition and Food
Science, Wayne State University, Detroit, MI, United States. Phone: (313)5772459, Fax: (313) 577-8616. E-mail: ahmad.heydari@wayne.edu.

26

Abstract
Aging

and

ββ-pol

+/−

deficiency (ββ-pol

)

interact

to

accelerate

the

development of malignant lymphomas and adenocarcinoma and increases
tumor bearing load in mice. Folate deficiency (FD) has been shown to
induce DNA damage repaired via base excision repair (BER) pathway. We
anticipated that FD and BER deficiency will interact to accelerate aberrant
crypt

foci

(ACF)

formation

and

tumor

development

in

ββ-pol

haploinsufficient animals. FD resulted in a significant increase in ACF
formation in wildtype (WT) animals exposed to 1, 2-dimethylhydrazine
(DMH), a known colon and liver carcinogen; however FD reduced
development of ACF in ββ-pol haploinsufficient mice. Prolonged feeding of
the FD diet resulted in advanced ACF formation and liver tumors in wild
type mice. However, FD attenuated onset and progression of ACF and
prevented liver tumorigenesis in ββ-pol haploinsufficient mice, i.e., FD
provided protection against tumorigenesis in a BER deficient environment
in all tissues where DMH exerts its damage. Here we show a distinct
downregulation in DNA repair pathways, e.g., BER, NER and MMR, and
decline in cell proliferation, as well as an upregulation in PARP,
proapoptotic genes and apoptosis in colon of FD ββ-pol haploinsufficient
mice. Moreover, we report that FD BER deficient mice show a significant
downregulation in mTOR pathway, which is implicated in cell proliferation
and survival. Our data indicate, therefore, that FD in BER deficient mice
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downregulates mTOR, inhibiting s-phase transit perhaps secondary to
depletion of cellular energy by PARP, promoting apoptosis and providing
protection against tumorigenesis.
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INTRODUCTION
Folate deficiency is an important public health concern because of the role
folate plays in the development of many different health problems, including
neural tube defects, cardiovascular disease, Alzheimer’s disease and cancer,
specifically colon cancer. It has been proposed that the carcinogenic properties of
folate deficiency may be related to a decrease in DNA methylation, perhaps as a
function of reduced S-adenosylmethionine (SAM) levels, an increase in the uracil
content of DNA or an increase in oxidative stress by alterations in thiol switches.
Folate deficiency has also been shown to increase (in cells, animal models and
humans) levels of single strand breaks (84, 111, 112, 85, 113), micronucleus
formation, (114, 115), chromosomal aberration (116, 117) and mutation
frequency (82, 83), all potentially downstream effects of high levels of uracil in
DNA and oxidative damage to DNA.
The DNA repair pathway for removal of uracil and oxidized bases is the
base excision repair (BER) pathway. The BER pathway is believed to repair
small, non-helix-distorting lesions in the DNA. It has been estimated to be
responsible for the repair of as many as one million nucleotides per cell per day
(47), stressing its importance in the maintenance of genomic stability. It has been
suggested that BER has evolved in response to in vivo exposure of DNA to ROS
and endogenous alkylation, and that this pathway suppresses spontaneous
mutagenesis (117). In the initial elucidation of the BER pathway the following
steps were involved: i) removal of the damaged base by a DNA glycosylase; ii)
incision of the phosphate backbone by an endonuclease; iii) synthesis of new
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DNA by a polymerase; iv) excision of the deoxyribose phosphate (dRp) moiety;
and v) ligation. This remains the predominant BER pathway and is clearly the
pathway for repair of uracil. DNA polymerase β (β-pol) performs the
polymerization steps in the predominant short patch BER pathway and appears
to perform the rate-limiting step, by virtue of its dRp lyase activity (53). In the
process of uracil removal and repair of oxidized bases, a transient formation of a
DNA

single

strand

break

occurs.

Our

laboratory

has

shown

that

haploinsufficiency in β-pol would result in persistence of the DNA single stand
breaks, where this persistence could result in DNA double strand breaks and
chromosomal aberration (60).

Based on current understanding of the role of a β-pol-dependent BER
pathway on removal of uracil, alkylated bases and oxidized bases, it is interesting
to determine the impact of β-pol haploinsufficiency on tumorigenesis. While the
homozygous β-pol knockout is embryonic lethal, the β-pol heterozygous knockout
mice are viable and fertile. We previously characterized this mouse model as
expressing 40-50% less β-pol mRNA and protein in various tissues and
determined that this mouse has 40-50% reduced in vitro BER activity in all
tissues tested (60). In addition, these animals exhibit an accumulation of
spontaneously arising single strand breaks and chromosomal aberrations with
age. Furthermore, in response to alkylating and oxidizing agents, an even greater
accumulation of single strand breaks and chromosomal aberrations, as well as an
increase in mutation frequency are observed in these mice (60).
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Moreover, β-pol haploinsufficient mice display an acceleration of normal, agerelated

tumors,

e.g.,

lymphomas,

developing

alongside

an

increased

susceptibility to epithelial tumors, e.g., adenocarcinomas, which do not typically
occur at a high incidence in C57BL/6 mice (77).

Based on the striking similarities between DNA damage induced by folate
deficiency and that induced by a reduction in BER capacity, we suggest a strong
association between BER and folate. We have reported previously that folate
deficiency overwhelms the capacity of BER through the inhibition of upregulation
of β-pol (80). It is feasible that the inability to induce β-pol when folate is deficient
results in a functional BER deficiency, providing a logical explanation for the
phenotype induced by folate deficiency. While a tight correlation between DNA
damage and cancer exists, it is necessary to evaluate preneoplastic lesions and
tumors arising in response to the interaction between β-pol loss and folate
deficiency. The purpose of this study is to determine whether β-pol
haploinsufficiency accelerates the development and/or aggressiveness of these
lesions in colon and liver in response to carcinogen, 1,2-dimethylhydrazine
(DMH). This study has important human health implications, as polymorphisms
within the human population may render individuals haploinsufficient for β-pol
and increase cancer risk by reducing their DNA damage tolerance.
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METHODS
Animals- Experiments were performed in young 4 to 6 month old
C57BL/6-specific pathogen free male mice and mice heterozygous for the DNA
+/-

polymerase β gene (β-pol

) (77). All practices performed on animals were in

agreement with the National Institutes of Health (NIH) guidelines for the care and
use of laboratory animals. Mice were backcrossed to the C57BL/6 background.
The Wayne State University Animal Investigation Committee approved the
animal protocol. Mice were maintained on a 12-h light/dark cycle and given water
ad libitum.
Diets and Carcinogenic Treatment- After acclimation for 7 days, wildtype
+/-

(WT) and β-pol

mice were randomly assigned to two dietary groups; a folate

adequate (FA) or folate deficient (FD) AIN93G-purified isoenergetic diet (Dyets,
Inc., Lehigh Valley, PA) as described previously (80). The FA group received a
folate adequate diet containing 2 mg/kg folic acid. The FD group received a
folate-deficient diet containing 0 mg/kg folic acid. Diets were stored at –20°C.
1% succinyl sulfathiazole was added to all diets. One week after commencement
of food ingestion, randomly selected mice from both FA and FD were injected i.p.
with 1,2-Dimethylhydrazine HCL (DMH, 30 mg/kg body weight) in 10mmol/L of
NaHCO3 (Fisher Scientific, Fair Lawn, NJ) once a week for 6 wks
(Figure2, panel A). Both food intake and body weights were checked twice
weekly to monitor for signs of of toxicity, e.g., weight loss, and the diets were
continued for 12 weeks.
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Aberrant colonic crypt (ACF) analysis- Animals were anesthetized under
CO2 asphyxiation, the abdominal cavity was opened and the colon excised,
rinsed with cold PBS, cut longitudinally, and fixed flat overnight in 10% neutral
buffered formalin. The colonic crypts were stained with 2g/L of methylene blue in
PBS for 5 min. The number of ACF and aberrant crypts per foci were determined
by light microscopy at 10X magnification in a blinded man ner.

Realtime PCR- Total RNAs were isolated from the colon mucosa of mice
using the RNeasy Mini Kit (Qiagen, Valencia, CA) per manufacturer's protocol.
cDNAs were synthesized from 1 µg RNA using random hexamer primers
(Promega, Madison, WI) and purified with the QIAquick PCR Purification kit
(Qiagen). The levels of cDNAs were quantified using a LightCycler real-time
PCR machine (Stratagene, La Jolla, CA). PCR reactions contained 3 µL purified
cDNA, 12.5 µL qPCR master mix, and 0.5 µmol/L each of sense and antisense
primers (Roche)(Table I). For all amplifications, PCR conditions consisted of an
initial denaturing step of 95°C for 5 minutes followe d by 40 cycles of 95°C for 10
seconds, and 60°C for 30 seconds, with a melting curve a nalysis from 60°C to
95°C to confirm specificity. External standards were pre pared by amplification of
cDNAs for each gene. The amplicons were cloned into pGEM-T Easy vector,
linearized with appropriate restriction enzyme, and used to prepare external
standard curves. The level of each transcript was normalized to GAPDH. Results
are expressed as mean values from five animals per experimental group.
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Western blot analysis- Western blot analysis was performed using 200µg
nuclear protein as previously described (118). Upon completion of SDS–PAGE,
the region containing the protein(s) of interest was excised and prepared for
Western blot analysis, whereas the remaining portion of the gel was stained with
GelCode blue stain reagent (Pierce Biotechnology) to ensure equal protein
loading. Western analysis was accomplished using affinity purified polyclonal
antisera developed against mouse β-pol. As an internal control for protein
loading, membranes were reprobed with anti-Lamin B antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) The bands were visualized and quantified using
a ChemiImager System (AlphaInnotech, San Leandro, CA) after incubation in
SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology,
Rockford, IL). Data are expressed as the integrated density value (I.D.V.) of the
band per ∝g of protein loaded.
Microarray assays- Total RNAs were isolated from the colon mucosa of
mice using the RNeasy Mini Kit (Qiagen, Valencia, CA) per manufacturer's
protocol. RNA samples were quantified with NanoDrop ND-1000 (NanoDrop
Technologies, Inc, Wilmington, DE) and 260/280 ratio in the range of 2.0-2.2 was
defined as acceptable. A quality check of the total RNA was performed using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). One micro liter of
total RNA sample was applied on RNA 6000 NanoChip, and the assay was run
on the Bioanalyzer to determine if the 18S and 28S ribosomal bands are defined
and to ensure no RNA degradation was present. Optimal concentration used to
check the RNA quality is 250ng/∝
∝l.
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Microarray

expression

profiling

was

conducted

by

Microarray

&

Bioinformatics Facility Core at Wayne State University (Institute of Environmental
Health Sciences, Detroit, MI) according to the manufacturer’s protocol. A
balanced block experimental design was used: 4 microarrays were completed for
each comparison, with each microarray representing 1 randomly selected labeled
mucosal sample from each experimental group paired with 1 randomly selected
FA WT labeled mucosal sample i.e. in total 4 mucosal RNA samples from FDWT
cohybridized with 4 FAWT, 4 FDWT DMH treated cohybridized with 4 FAWT and
+/-

4 FD β-pol

DMH cohybridized with 4 FAWT treated, representing 4 micorarrays for

each experimental comparison. Samples on a given array were oppositely labeled
with Alexa 647 and Alexa 555 dyes. The four microarrays for a given
+/-

group (i.e., WT untreated, WT DMH or β-pol

DMH treated) represent samples

from eight separate mice, providing consideration of biological variation. In total,
+/-

12 arrays representing 24 mice (8 WT, 8 WT DMH-treated, 8 β-pol

DMH-

treated) were completed. Dye swaps were used to account for dye bias effects
such that of the four arrays in a given phenotype group, two had FD treated
samples labeled with Alexa 647 co-hybridized with control samples labeled with
Alexa 555 while the other two arrays within the same phenotype group had
opposite dye orientations. Microarrays were scanned using the Agilent dual laser
DNA micorarray scanner model G2565AA, with 10 micron resolution.
Microarray gene profile analysis- Microarray image analysis was
performed with Agilent Feature Extraction software, version A.5.1.1. Hierarchal
Clustering analysis was performed using GeneSpringGX V10 (Agilent
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Technologies) software, and the parameters were set for centroid linkage which
calculates the euclidean distance between the respective centroids of two
clusters. False discovery rate for FDWT was 5.1%, 1.7% for FDWT DMH treated
+/-

and 0.39% for FD β-pol

DMH-treated experimental groups. Heatmaps were

created by inputting accession numbers of differentially expressed genes, at
+/-

p<0.001, for FDWT and FD β-pol

DMH-treated experimental groups through

DAVID functional annotation. Outputs revealed gene onotologies of differentially
expressed genes, which were than compared to created differentially expressed
gene lists of DAVID biological processes, such as apoptosis and DNA repair.
+/-

Data sets were then combined for FDWT and FD β-pol

DMH-treated to 1 large

data set in order to create heatmaps for each biological function. Gene ontology
analysis was performed using Gene Ontology Tree Machine (GOTM),
(Bioinformatics,Vanderbilt University), applying differentially expressed genes as
depicted in the heatmaps`. We chose a single gene set analysis, where GOTM
compares the distribution of single gene set in each GO category to those in an
existing reference gene list from the mouse genome, identifying GO categories
with statistically significant enriched gene numbers as determined by the
hypergeometric test (p<0.01) (119, 120). Real time quantitative RT-PCR was
used to confirm the data obtained for selected genes in DNA repair pathways as
described above.
Terminal deoxynucleotidyl transferase-mediated nick-end labeling of
apoptotic cells in situ- Colon tissues were dissected, opened longitudinally, fixed
in 10% neutral buffered formalin, embedded in paraffin wax then cut into 5 µm-

36
thick sections. Sections were put on slides for the in situ terminal
deoxynucleotidyl tranferase-mediated nick-end labeling (TUNEL) (CHEMICON
International Inc., Temecula, CA) as per manufacturer’s protocol. Cells with
positive staining (brown staining) were considered as apoptotic cells and the
number of apoptotic cells was determined as the percentage per crypt.
5-Bromo-2-deoxyuridine (BrdU)-staining of proliferating cells in situ- Two
hours prior to CO2 asphxyation, mice were injected i.p. with a BrdU solution (10
mol/L, 1 mL per 100 g body weight) (5-Bromo-2’-deoxy-uridine Labeling and
Detection Kit ll, Roche Diagnostic, Mannheim, Germany) to immunostain
proliferating cells, following manufacturers instructions for paraffin-embedded
tissues. Briefly, after CO2 asphyxiation, as mentioned above, colons were
excised, and fixed in formalin. The tissue was then embedded in paraffin and
sections of 3 – 5 ∝m were cut longitudinally the full length of the colon. Tissues
were incubated in 10 ∝mol anti-BrdU monoclonal antibody for 1 hr at 37°C
followed by incubation with anti-mouse-Ig-alkaline phosphatase. The labeling
index was used to quantify cell proliferation, defined as the percentage of BrdUpositive cells per crypt.
Tumor Analysis- All animals were sacrificed at 40 weeks after the last
dose of DMH, by asphyxiation with carbon dioxide, and all organs and tissues
were examined for grossly visible lesions. Liver and colon tissues, including
gross abnormalities, were fixed in 10% neutral buffered formalin, trimmed,
embedded in paraffin, sectioned to a thickness of 5 to 6 µm, stained with H&E,
and examined microscopically. Preparation of slides for histopathology
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evaluation was performed by pathologists at the Department of Pathology,

Wayne State University.
Statistical

analysis-

Statistical

significance

between

means

was

determined using ANOVA, followed by the Fisher’s least significant difference
test where appropriate (121). P-values less than 0.05 were considered
statistically significant.
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RESULTS
Induction of aberrant crypt foci (ACF) formation in DNA polymerase β
haploinsufficient mice in response to dimethyl hydrazine (DMH)- The purpose of
this study was to determine the impact of BER deficiency on colon
carcinogenesis in an animal model. In the first series of experiment, we
determined the impact of β-pol heterozygosity on the development and
progression of ACF in DNA polymerase β heterozygous knockout mice of
C57BL/6 background, characterized previously by our laboratory (122). We have
previously observed a deficiency in β-pol gene expression in various tissues of β+/-

pol

mice (brain, liver, spleen and testes) with a concurrent decline in BER

capacity (122). As shown in Figure 1A, in this study we have confirmed similar
+/-

decline in expression of β-pol gene in the colon mucosa of the β-pol

mice

suggesting a parallel decline in BER activity in the colon of these mice.
It is well established that carcinogen-induced ACF are early indicators of
initiation of colon cancer in animal models (92, 123, 124). In this study, we
utilized 1,2-dimethylhydrazine (DMH), an established colon and liver carcinogen.
It is proposed that DMH converts to the active metabolites azoxymethane and
methylazoxymethanol in the liver, which are then transported to the colon via
blood and bile (125). DMH in these tissues exerts its damage to DNA by
induction of alkylation damage (O6-meG and N7-meG) as well as oxidative
+/-

damage. We have previously demonstrated that the β-pol

mouse is not

sensitive to the O6-meG lesion (removed by direct reversal), but is sensitive to
the N7-meG lesion processed by BER pathway (126). Additionally, we have
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+/-

observed increased accumulation of DNA single strand breaks in the β-pol

mouse in response to oxidative stress, as compared to its wildtype counterpart
(60). Thus, we postulated that β-pol haploinsufficiency may predispose animals
to increased colon carcinogenicity and induce development of ACF in response
to DMH. At the outset of the current study, mice were injected with 30 mg/kg
body weight DMH for 6 weeks to induce ACF. Six weeks after the final injection,
the mice were sacrificed and the level of ACF in colon was determined. As
shown in Fig. 1B, wildtype and β-pol haploinsufficient untreated mice did not
display any ACF in their colon. Thus, β-pol haploinsufficiency and subsequent
deficiency in BER capacity is not enough to induce ACF in mice, suggesting that
β-pol is a low-penetrance gene, requiring a high penetrance environmental insult,
e.g., DMH or nutritional deficiency, for the damage to accumulate. Furthermore,
as shown in Fig. 1B, β-pol

+/-

DMH-treated mice exhibited a significantly higher

level of ACF formation (67% higher) as compared to wildtype counterparts
+/-

(15.4±1.8 versus 29.7±1.4, for wildtype and β-pol

mice, respectively, p<0.01).

These findings indicate that β-pol haploinsufficient mice are more sensitive to
+/-

DMH, i.e., β-pol

animals show an inability to respond to oxidative stress and

alkylation damage as compared to their wildtype littermates. Interestingly, no
significant differences in ACF size and aberrant crypts per focus were observed
in these animals. Having confirmed these findings, we were interested in the
effect of folate deficiency in a BER deficient environment on the response to
DMH.
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Impact of folate deficiency and β-pol haploinsufficiency on ACF formation
in colon- Folate deficiency has been suggested to impact SAM/SAH ratio (126),
increase uracil incorporation into DNA (a substrate for BER pathway) and induce
oxidative stress in animals. Subsequently, to elicit the role of folate deficiency on
+/-

ACF formation in wildtype and β-pol

animals, animals were fed either a folate

adequate (FA, 2 mg/kg folic acid) or folate deficient (FD, 0 mg/kg folic acid) diets
as outlined in Figure 2A. To induce severe folate deficiency, 1% Succinyl
Sulfathiazole was added to the diet deficient in folic acid to prevent synthesis of
folic acid in the gut by bacteria. The animals’ food intake and body weight were
monitored weekly. Folate deficiency did not affect body weight while it reduced
the plasma folate level by 90% as determined by a SimulTRAC-SNB radioassay
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kit for vitamin B12 ( Co) and folate (

125

I) per the manufacturer's protocol (ICN

Diagnostics, Orangeburg, NY) as described previously (80). After one week on
+/-

respective diet, the wildtype and β-pol

mice were injected with DMH once per

week for 6 weeks (Figure 2A). Six weeks after the final injection DMH-treated
and control mice were sacrificed and the levels of ACF in colons were
determined. Interestingly, no ACF was observed in control mice fed a folate
adequate and/or folate deficient diet. Thus, β-pol haploinsufficiency in
conjunction with folate deficiency was not enough to induce ACF formation in
untreated mice. However, DMH-induced ACF were observed in all DMH-treated
animals. As observed by other laboratories (127, 128), folate deficiency resulted
in a significant increase in ACF formation in wildtype animals treated with DMH
as compared to the FA counterpart (15.4±1.8 versus 37.6±5.2, for FA and FD
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mice, respectively, p<0.01), i.e., folate deficiency predisposes mice to increased
colon carcinogenesis in response to DMH. As shown in Figure 2B, DMH-induced
+/-

ACF was confirmed and significantly higher in FA β-pol

mice as compared to

their wildtype littermates. Based on these findings and in view of the fact that FD
resulted in further decline in β-pol expression in colon mucosa (Figure 3), we
anticipated that β-pol haploinsufficient mice would display a dramatic
development of ACF when folate is deficient. However, we observed a
+/-

significant reduction in the formation of ACF in β-pol

mice when compared to

their wildtype counterparts in a folate deficient environment (50% reduction;
+/-

37.6±5.2 versus 18.3±4.1, for wildtype and β-pol

mice fed a folate deficient

diet, respectively, p<0.01, Figure 2B). It has been proposed that the size of ACF
and number of aberrant crypts per focus could be a more appropriate indicator of
colon tumorigenesis. As shown in Figure 2C, no significant differences in the
number of aberrant crypts per focus were observed in all experimental groups
treated with DMH. These data indicate that β-pol haploinsufficiency attenuate
carcinogen-induced ACF development when folate is deficient.
To determine whether prolonged folate deficiency increases ACF
progression or results in ACF regression, wildtype mice were maintained on their
specific diets for 40 weeks post DMH treatment. After sacrifice, colons were
macroscopically examined for the development of ACF and the number of
aberrant crypts per focus (Figure 4A). As shown in Figure 4B, as has been
reported elsewhere, there was a lack of further increase in ACF numbers, but
rather a regression of ACFs as well as, a further development to larger ACF with
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increased aberrant crypts per focus in these mice. Although we observed no
significant change in crypt multiplicity at 6 weeks post treatment for any group
studied, the number of crypts per focus significantly increased in FD mice as
compared to their FA counterparts after 40 weeks in wildtype mice (7.63±0.4
verses 6.33±0.4, for FD and FA mice, respectively, p<0.05). Moreover, ACF in
FD mice displayed a well defined elevation above the surrounding mucosa
compared to its FA counterpart which appeared flat (Fig. 4A, Panels IV). Thus
based on the notion that the size of ACF and the number of aberrant crypts per
focus are better indicator of tumor formation, folate deficiency does not only
increase the number of ACF in response to DMH early on, but its adverse impact
persist resulting in further development of aberrant foci and formation of
microscopic adenoma, while this phenomenon could be hampered where β-pol is
deficient. Accordingly, it was important to evaluate the experimental groups for
tumor analysis. Determining tumor incidents in these mice is important as these
data potentially shed light on the impact of BER deficiency on colon tumors in a
folate deficient environment, and determine potential continuity between ACF
development and formation and metastasis of tumors.
Analysis of pathology in β pol haploinsufficiency and wildtype counterparts
in response to folate deficiency and DMH treatment- Having established the
+/-

DMH-induction of ACF in colon of β-pol

mice and their wildtype counter parts

fed a FA and/or FD diet, we studied the impact of folate deficiency and DMH
treatment on tumor formation in these animals, based on the known impact of
DMH on colon and liver tissues. In this study, we followed animals for 40 weeks
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after the last DMH treatment, to determine the incidence of tumor formation as
outlined in Figure 5A. Analysis of formalin-fixed and methylene blue stained
colons provided evidence of advanced ACF in the colon of wildtype FD (Figure 4,
IV) mice treated with DMH as compared to FA mice (Figure 4, III). In other words,
while a more defined elevation above the surrounding mucosa was observed in
ACFs of FD fed mice, the FA mice displayed less developed ACF. Upon
dissection of animals, we perceived gross changes in the pathology of the
liver in FD DMH-treated mice (50% tumor formation) and FA DMH-treated β+/-

pol

(100% tumor formation). As shown in Figure 5B, panels II and III, the
+/-

architecture of the liver tissue in all the FD WT and β-pol

fed a FA diet,

demonstrated an atypical morphology depicting progression of tumors. In
contrast, there were no visible changes in the liver for wildtype mice consuming a
+/-

FA diet and β-pol

+/-

animals fed a FD diet. Taken together, FD WT and β-pol

fed a FA diet with DMH treatment show more developed ACF and tumor
+/-

formation than FA WT DMH-treated and FD β-pol

animals. This is suggestive,

yet again, of haploinsufficiency conferring protection when exposed to
oxidative/alkylation stress induced by DMH treatment in a folate deficient
environment. Based on these data, it is inviting to suggest that β-pol
haploinsufficiency in combination with folate deficiency might impact cell cycle
arrest and apoptosis in response to DMH, thus impacting ACF development and
consequent tumor formation. Accordingly, we wanted to determine the impact of
β-pol haploinsufficiency and folate deficiency on gene expression in mucosal
tissue of the colon.
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Effects of folate deficiency on gene expression in colon mucosal cellsHaving seen a difference in colon pathology, as aforementioned, we wanted to
+/-

determine differential expression of genes in colon tissues of β-pol

mice

subjected to DMH in a folate deficient environment. In order to ascertain possible
mechanisms of reduced ACF and tumor formation, we decided to
+/-

conduct a microarray analyses on FD β-pol

DMH-treated and FD WT DMH-

treated colon mucosa, relative to FA WT. As depicted in the scatter plots of
differentially expressed genes, there was a marked difference in expression of
many genes in DMH treated β-pol haploinsufficient mice subject to a folate
+/-

deficient environment (4621 upregulated, 5757 downregulated in FD β-pol

DMH-treated versus 528 upregulated, 557 downregulated in FD WT mice) (Figure
6A). In other words, β-pol haploinsufficiency and DMH-treatment resulted in more
extensive differential expression of genes as compared to wildtype untreated
mice. To authenticate the outcome of microarray analysis, we performed
quantitative RT-PCR using FullVelocity™ SYBR ® Green QRT-PCR
Reagents (Stratagene) on candidate genes depicted as differentially expressed
through microarray analysis. The candidate genes studied included UNG, MPG,
β-pol, XRCC1, ligase 3 and RAD51li. qRT-PCR results for the 6 genes selected
were consistent with microarray data. All were significantly downregulated in the
FD β-pol

+/-

DMH-treated mice (p<0.05) (Table IV). Having confirmed the validity

of microarray findings, we wanted to identify the inter-relationships that existed
between the abundance of differentially expressed genes.
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Based on our assessment of a possible role of DNA repair and apoptosis
we used DAVID biological function to determine the changes in individual gene
expression related to these two pathways. Once identified, we generated a series
of hierarchal clustered heatmaps based on intensity of gene expression from raw
data files (Figure 6B). Hierarchal clustering assisted in exploring the relationships
that exist amongst the statistical data identified in the microarray analysis. Here
we show that upon conducting a clustered analysis, all the data demonstrates a
thrust toward a reduction in DNA repair and an upregulation in
apoptotic related gene activity in the FD β-pol

+/-

DMH-treated mucosal tissue. In

contrast, WT-untreated counterparts had a propensity toward either no difference
in or slight upregulation in DNA repair and a downregulation in proapoptotic gene
expression. Furthermore, FD WT DMH-treated groups showed either no
difference or an upregulation in DNA repair capacity and an upregulation in
apoptotic.
To further characterize the differences in gene expression, we input
differentially expressed genes, from the raw data files, into Directed acyclic
Graphs (DAG) view of Gene ontology to acquire clusters of statistically (p<0.01)
enriched differentially expressed genes according to their gene ontology. In this
analysis, all gene names from raw data files were input into GOTM without
reference to significance or intensity levels. Here, again, even with limited data
input, we confirmed enrichment in DNA repair response and apoptotic activity FD
+/-

β-pol β-pol

DMH-treated. As shown in Figure 7, the ontology groups enriched

at program cell death and apoptosis, as well as, in BER, NER and recombination
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repair all converging on DNA damage response, signal transduction and
induction of apoptosis.
Analyzing expression data with DAVID biological processes highlighted
several genes related to promotion of apoptosis and DNA repair activity (Table II,
III, IV). Interestingly, we observed a distinct decline in overall DNA repair activity,
including but not exclusive to BER (UNG, Apex, and β-pol), mismatch repair
(MSH2 and MSH3), and nucleotide excision repair (ERCC2 and Xpc) (Table I).
In addition, we see a downregulation in FRAP1 (mediates cellular response to

DNA damage) in β-pol haploinsufficient and FD WT mice, with no change in
gene expression in FD WT DMH-treated colonic mucosa. In contrast, there was
an enhanced expression of several proapoptotic genes, including genes involved
in intrinsic/extrinsic apoptotic pathways (CASP 4 and CASP8), TNF signaling
(Tnfsf12 and Tnfrsf26), as well as, GAS1 and Trp63 (Table II). All of these data
suggest enhanced programmed cell death, either based on enhanced apoptotic
activity, forgoing DNA repair, or lack of response of DNA repair pathways to
cellular damage, increasing the sensitivity of apoptotic related pathways.
Interestingly, the differential expression of genes in the WT FD DMH-treated
colonic mucosa was either not differentially expressed or upregulated for DNA
repair, with the exception of β-pol and upregulated in apoptosis, apart from a
downregulation in CASP 3. In addition, FD WT colonic mucosa were either not
differentially expressed or for the most part, slightly upregulated for DNA repair
and showed reduction in apoptotic activity suggesting that in addition to folate
deficiency, a compromised BER pathway is required to trigger apoptosis in DMH-
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treated mice. In view of these findings, we wanted to further confirm these results
through a series of immunohistological experiments.
Evaluation of apoptotic and proliferative activity in colonic mucosal cells-

Having determined the impact of β-pol haploinsufficiency on colon and liver
tissue; we wanted to establish why BER insufficiency attenuates development of
lesions in the face of deleterious surroundings of DMH-induced carcinogenesis
and folate deficiency. We, therefore, conducted both apoptotic and proliferative
assays because maintenance of mucosal integrity is reliant on the regulation of
these two entities, i.e., development of ACF may arise if this integrity becomes
compromised. To determine apoptotic activity in our experimental groups, we
measured apoptosis in colon using the TUNEL assay. Firstly, folate deficiency
increased apoptotic body in wildtype animals (data not shown). Interestingly,
folate deficiency induced a greater level of apoptotic activity in β-pol
haploinsufficient mice as compared to wildtype counterparts (Figure 8A, IV).
Next, to characterize the effect of β-pol heterozygosity and folate deficiency on
cell proliferation in response to DMH treatment, we examined the proliferative
activity of colon tissues examining BrdU incorporation. As shown in Figure 8D, I,
+/-

FA β-pol

mice showed significantly more proliferation (BrdU incorporation) as

compared to FD β-pol+/- mice. Thus, the TUNEL and BrdU assays confirmed the
differential expression observed in microarray analysis, suggesting that folate
+/-

deficiency provide protection against tumorigenesis in DMH-treated β−pol

mice

by altering the balance between DNA repair and apoptotic pathway favoring
apoptosis.
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Fig 1. Impact of β-pol heterozygosity on expression of β-pol in colon mucosa and ACF formation
in colon of mice treated with DMH. (A) Analysis of β-pol expression, mRNA and Protein levels,
in mucosa from wildtype and β-pol haploinsufficient mice. Expression of β-pol gene was
determined using a real time PCR technique and the level was normalized base on GAPDH
expression. Protein level was quantified using a western blot analysis and normalized based on
the Lamin b protein level. (B) Wildtype (WT) mice and β-pol haploinsufficient mice received
either no treatment (controls) or i.p. treatment with DMH for 6 weeks at 30 mg/kg body weight
(DMH treated). Colons were processed after CO2 asphyxiation of mice as described in materials
and methods. Colons were analyzed under light microscopy to visualize the number of ACF per
mouse colon (ACF/mouse). Bars, SE, * , P<0.01.
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Figure 2
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Fig 2. Panel A: Experimental Design: WT and β-pol mice were fed either a folate adequate (2
mg/kg, FA) or a folate deficient (0 mg/kg, FD) diet for 12 weeks. After one week of ingestion of
respective diets, mice were injected with 30 mg/kg body weight DMH for 6 weeks. Six weeks
after final injection, animals were sacrificed by CO2 asphyxiation. Panel B and C: ACF
+/formation and crypt multiplicity in colon of β-pol mice consuming a folate deficient diet. WT
+/and β-pol received either a FA diet or FD diet and subjected to either no treatment (control) or
i.p. treatment with DMH for 6 weeks at 30 mg/kg body weight (DMH treated). After sacrifice
colons were processed as per materials and methods. Colons were analyzed under light
microscopy to visualize the number of ACF per mouse colon (ACF/mouse) (B) and the number
of crypts per focus (C). Bars with different letters indicate significant differences at P < 0.05.

51

Figure 3
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Fig 3. Impact of folate deficiency and DMH treatment on expression of β-pol in colon mucosa of
+/β-pol mice. Expression of β-pol gene was determined using a real time PCR technique and the
level was normalized base on GAPDH expression as described in materials and methods. Bars
with different letters indicate significant differences at p < 0.01.
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Fig 4. Impact of long term feeding on ACF formation and Crypts Multiplicity. Comparison of
ACF formation and crypt multiplicity in mice fed either a FA or FD diet at 6 weeks versus 40
weeks post DMH treatment. Panel A: (I) Normal colonic crypts, (II) ACF formation in FD
environment 6 weeks post DMH, (III) ACF formation in mice fed FA diet 40 weeks post DMH,
and (IV) number of ACF of mice fed a FD diet 40 weeks post DMH treatment. Arrows depict
area of aberrant crypt formation. Panel B: Relative number of ACF/mouse in mice fed either a
FA or FD diet 6 weeks or 40 weeks post DMH treatment, respectively. Panel C: Number of
aberrant crypts per focus in mice fed either a FA or FD diet 6 weeks or 40 weeks post DMH
treatment, respectively. Bars with different letters indicate significant differences at P < 0.05.
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II
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and folate deficiency on induction of tumors in DMH-treated mice. A.

Feeding study was conducted as depicted in Figure 2. The mice were sacrificed 40 weeks after last
treatment by CO2 asphyxiation and incidence of tumor progression was assessed. B.
Exemplary H&E micrographs showing tumor formation in liver sections from (I) WT FA (II)
+/+/WT FD, (III) FA β-pol and (IV) FD β-pol mice treated with DMH. The % value represents
the percent of mice with visible liver tumor formation. All wildtype animals fed the FD diet
showed liver tumors through H&E analysis.
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Figure 6
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Fig 6. Scatter plot of differentially expressed genes and heat map representation of microarray
data for proapoptotic and DNA repair differentially expressed genes. A. Scatter plot of
+/+/differentially expressed genes from colon mucosa from FD β-pol relative to FA β-pol tissues
and WT FD relative to WT FA tissues included in the Agilent Whole Mouse Genome
oligonucleotide micorarray containing probes for over 41,000 well characterized genes. B.
Hierarchal Clustering analysis was performed using GeneSpringGX V10 (Agilent Technologies)
software, and the parameters were set for centroid linkage which calculates the euclidean distance
between the respective centroids of two clusters. A heat map in quadruple (A, B, C, and D) for
each condition representing proapoptotic and DNA repair genes are shown.
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Figure 7
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Fig 7. DAG view of gene ontology analysis, of colonic mucosal tissue in FD β-pol

versus FA

WT. Blue boxes indicate enrichment of expression of genes related to DNA repair. Red boxes
indicate enrichment of expression of genes related to apoptosis.
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Figure 8
C

A

I

I

II
FA WT DMH

FA β-pol

FD WT DMH

III

+/-

FD β-pol

DMH

+/-

FD β-pol DMH

DMH

III

IV
+/-

FA β-pol

II
+/-

IV
+/-

FA β-pol

DMH

B

+/-

FD β-pol

DMH

D

cry
pt

1.4

p
e
r

1.6

1.2

b

b

10
8

o
d
y

1.0

c

Apopto
tic

0.8

6

0.6

4

0.4

d

*

2

0.2

0

0

β-pol

WT

+/-

β-pol

WT

FA

FD

DMH Treated

+/-

+/-

FA β-pol

+/-

FD β-pol

DMH Treated

DMH

59

+/-

Fig 8. Impact of β-pol and folate deficiency on apoptotic activity and induction of proliferation
in colonocytes. A. Representative photomicrographs showing TUNEL-positive staining in cells
+/+/(brown) of colonic mucosa. (I) WT FA, (II) WT FD, (III) FA β-pol and (IV) FD β-pol mice
+/treated with DMH. B. Tally of the TUNEL-positive apoptotic cells. WT and β-pol were fed
either a FA or FD diet and subjected to DMH treatment. Colon tissue was processed, TUNEL
assay conducted and percent apoptotic cells were calculated as described in methods. Means
without a common letter differ, P < 0.01. C. Representative photomicrographs showing H&E of
+/+/colonic mucosa. (I) FA β-pol and (II) FD β-pol mice treated with DMH. Representative
+/micrographs showing BrdU staining (brown) of colonic mucosa. (III) FA β-pol and (IV) FD β+/pol mice treated with DMH. Proliferation Analysis: β-pol haploinsufficient mice were treated
as described in materials and methods. Briefly, 2 hours prior to sacrifice mice were injected i.p.
with BrdU (2.16mg/kg body weight). Colon segments were fixed in 10% formalin and embedded
in paraffin. BrdU incorporation was detected by immunostaining as described in materials and
methods. D. Enumeration of positive proliferation. Percent cell proliferation was conducted as
detailed in materials and methods. * indicate differences at P<0.01.
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Gene
UNG
ββ-pol
Lig3
MPG
Rad51l1
GAPDH

Sense Primer Sequences

Antisense Primer Sequences

5’-AACAGGCTTGGTTGGCGAAGG-3’

5’- CGGCTGGCATCCTAAGACATC-3’

5’-TACGACCAGAGGCATACAGGGACT-3’

5’-ACCAACTGGGACGACATGGAGAAG-3’

5’-AAGTTCGCATTCAGGTCTAAGC-3’

5’-AGAGGCTCACAAGTTCCATCC-3’

5’-GGAGACTGAGGCATACTTGG-3’

5’-GACTAGAGACATTCAAGCAGA-3’

5’-ATCTCTCACCGGCATTCCTGTCTACTACCC-3’

5’-CCGCCATCTCAACCAGTCTCTCAGCAG-3’

5’-GCCAGCACGCAAAAGGTCACATTGT-3’

5’-AGTTCCGGAAAGCACAGCCAGGATG-3’

Table I: Primer Sequences for Real-Time PCR
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Table II. Summary of the effect of folate deficiency on DNA repair pathway genes in wildtype,
+/wildtypeDMH-treated and β-pol DMH-treated mice*
+/-

Accession no. Gene name

WT WT B-POL
- DMH DMH

NM_009764
NM_009765
NM_178309
AF236887
AK048970
NM_021385
NM_011236
NM_009015
NM_011234
NM_009013
NM_009014
NM_011677
NM_133250
NM_181569
NM_009687
AK047252
NM_021498
NM_010715
NM_010716
AK048442
NM_008628
NM_010829
NM_013600
NM_146235
NM_007949
NM_009531
NM_016925
NM_175027
NM_007985
NM_178912
NM_018736
NM_011045
NM_009532
NM_028875
NM_009533
NM_010247

-1.7
-1.6
-1.8
-1.3
-1.6
-1.7
ns
-2.0
-1.7
-1.9
-2.4
-1.6
-1.5
-1.4
-1.7
-1.5
-1.3
-1.3
-1.3
-1.4
-1.5
-1.4
-1.8
-2.0
-1.3
-1.4
-1.4
-1.6
-1.3
-1.4
-1.3
-1.3
-1.2
-1.7
-1.4
-1.5

Breast Cancer 1
Breast Cancer 2
BRCA1 interacting protein C-terminal helicase 1
Ataxia telangiectasia and Rad3 related
Ataxia telangiectasia mutated homolog (human)
RAD18 homolog
RAD52 homolog (S. cerevisiae)
RAD54 like
RAD51 homolog
RAD51 associated protein 1
RAD51-like 1
Uracil DNA glycosylase
MutY homolog (E. coli)
N-methylpurine-DNA glycosylase
Apurinic/apyrimidinic endonuclease 1
Polymerase (DNA directed), beta
Polymerase (DNA directed), epsilon 3 (p17 subunit)
Ligase I, DNA, ATP-dependent
Ligase III, DNA, ATP-dependent
Ligase IV, ATP-dependent
MutS homolog 2
MutS homolog 3
MutS homolog 5
Excision repair cross-complementing complementation group 6 - Like
Excision repair cross-complementing complementation group 2
Xeroderma pigmentosum, complementation group C
Fanconi anemia, complementation group A
Fanconi anemia, complementation group B
Fanconi anemia, complementation group C
Fanconi anemia, complementation group M
Meiotic recombination 11 homolog A
Proliferating cell nuclear antigen
X-ray repair complementing defective repair in Chinese hamster cells 1
X-ray repair complementing defective repair in Chinese hamster cells 3
X-ray repair complementing defective repair in Chinese hamster cells 5
X-ray repair complementing defective repair in Chinese hamster cells 6

* P<0.01; ns, no significant difference

ns
1.4
ns
1.2
ns
ns
1.4
ns
ns
1.4
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
1.4
ns
ns
ns
ns
ns
ns
ns
ns
ns

ns
1.5
ns
ns
ns
ns
1.2
ns
1.6
2.0
1.3
ns
ns
ns
1.4
ns
ns
1.5
ns
ns
ns
ns
ns
1.8
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
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Table III. Summary of the effect of folate deficiency on apoptotic pathway genes in wildtype,
+/wildtypeDMH-treated and β-pol DMH-treated mice*

Accession no.

Gene name

NM_008086
NM_011641
NM_009367
NM_008337
NM_008329
NM_009812
NM_007609
XM_139295
NM_175362
NM_011817
AK010701
NM_025858
NM_013693
NM_010177

Growth arrest specific 1
Transformation related protein 63
Transforming growth factor, beta 2
Interferon gamma
Interferon activated gene 203
Caspase 8
Caspase 4, apoptosis-related cysteine peptidase
Caspase recruitment domain family, member 6
Caspase recruitment domain family, member 11
Growth arrest and DNA-damage-inducible 45 gamma
Death effector domain-containing DNA binding protein 2
Scotin gene
Tumor necrosis factor
Fas ligand (TNF superfamily, member 6)
Mus musculus tumor necrosis factor (ligand) superfamily,
member 10
Tumor necrosis factor (ligand) superfamily, member 12
Tumor necrosis factor receptor superfamily, member 21
Mus musculus tumor necrosis factor receptor superfamily,
member 26
Nur77 downstream gene 1
Caspase 3
ELL associated factor 2

NM_009425
NM_011614
NM_178589
NM_175649
NM_183322
NM_009810
NM_134111

* P<0.01; ns, no significant difference

WT
-

+/-

WT B-POL
DMH DMH

8.8
27.4
11.4
6.2
5.2
1.4
2.1
1.4
3.6
1.5
1.6
1.5
3.9
2.1

ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns

ns
ns
ns
ns
2.1
ns
1.5
ns
ns
ns
ns
ns
ns
ns

2.0
2.2
1.4

ns
ns
ns

ns
ns
ns

4.1
2.5
ns
2.6

ns
ns
ns
ns

ns
3.8
-1.4
ns
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Table IV. Summary of the effect of folate deficiency on antiapoptotic pathway genes in wildtype,
+/wildtypeDMH-treated and β-pol DMH-treated mice*
+/-

Accession no.

Gene name

NM_134138

Tumor necrosis factor superfamily, member 5-induced
protein 1
Apoptosis, caspase activation inhibitor
Caspase recruitment domain 4
Transforming growth factor, beta receptor associated protein
1
Bcl2-like 1
BCL2-like 12 (proline rich)
Bcl2-associated athanogene 1
Bcl2-associated athanogene 3
Transmembrane BAX inhibitor motif containing 4
Baculoviral IAP repeat-containing 5
E2F transcription factor 1
Mdm2, transformed 3T3 cell double minute p53 binding
protein
FK506 binding protein 12-rapamycin associated protein 1

AK046479
NM_172729
AK018453
NM_009743
AK041357
NM_009736
AJ250687
BC027637
NM_009689
NM_007891
NM_134092
BC043920

* P<0.01; ns, no significant difference

ββ-pol
WT WT
- DMH DMH
-1.4

ns

1.3

-1.7
-1.4
-1.6

ns
ns
ns

ns
ns
ns

-1.4
-1.3
-1.2
-2.8
-1.3
-2.8
-2.0
-1.5

ns
1.8
ns
ns
ns
ns
ns
1.3

ns
ns
ns
ns
ns
ns
ns
1.6

-1.8

ns

ns

64

Table V. Confirmation of differences observed in Gene Array using real-time PCR for the effect of folate
deficiency on DMH-treated knockout mice*

Accession no.

Gene name

AK047252
NM_011677
NM_181569
NM_010716
NM_009014

Polymerase (DNA directed), beta
Uracil DNA glycosylase
N-methylpurine-DNA glycosylase
Ligase III, DNA
RAD51-like 1

* P<0.01

Array
-1.5
-1.6
-1.4
-1.4
-2.4

Realtime
PCR
-1.8
-1.9
-1.3
-7.0
-4.4
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DISCUSSION

In this study we examined the impact of BER deficiency on colon
carcinogenesis in a mouse model. BER processes endogenous damage, as
such, our interest has been in developing model systems to test the processing of
endogenous damage and determine the impact of BER deficiency on
tumorigenesis in vivo. Our laboratory has previously characterized DNA
polymerase β heterozygous knockout mice displaying haploinsufficiency in β-pol
gene expression in various tissues (Brain, Liver, spleen and testes) with a
concurrent decline in BER capacity (122). These animals exhibit an accumulation
of spontaneously arising single strand breaks and chromosomal aberrations with
age (60). Additionally, in response to alkylating and oxidizing agents, an even
greater accumulation of single strand breaks and chromosomal aberrations, as
well as an increase in mutation frequency are observed in these mice (60). In this
study, we show a significant decline in β-pol expression in the colon of the
knockout mice as compared to their wildtype littermates, suggesting a BER
deficiency in the colon of these mice. Using the same animal model, Allen et al.
(129) showed that normal β-pol activity is necessary for maintaining low germline
mutation frequency. We previously observed in n β-pol haploinsufficient mice, an
acceleration of normal, age-related tumors, e.g., lymphomas, developing
alongside an increased susceptibility to epithelial tumors, e.g., adenocarcinomas,
which do not typically occur at a high incidence in C57BL/6 mice. Additionally, we
+/-

have shown that in β-pol

mice, levels of single strand breaks accumulate in
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response to oxidative stress, to a greater extent than they do in the wildtype mice
(122). Interestingly, in this study despite compromised BER capacity, the β-pol
mice do not display any evidence of spontaneously induced preneoplastic lesion
in their colon confirming β-pol’s low penetrance. Noting this, we wanted to know
the impact of exposure of animals to DMH, an established inducer of colon and
liver carcinogenesis. DMH is a DNA damaging agent that induces alkylation
damage (O6-meG and N7-meG) (130) as well as oxidative damage (131). We
+/-

have previously demonstrated that β-pol

mice are not sensitive to the O6-meG

lesion (removed by direct reversal), but is sensitive to the N7-meG lesion
+/-

processed by BER pathway (122). Intriguingly, in this study, when the β-pol

mice were treated with DMH a significant increase in ACF formation relative to
wildtype counterparts were observed. Thus, herein, we have confirmed that the
β-pol heterozygous mice are predisposed to preneoplastic lesions and cancer
development, primarily by reducing tolerance to the DNA damage in response to
DNA damaging agent, DMH. As such, these manipulations gave rise to an animal
model of colon carcinogenesis for future study.
While the mechanism by which folate deficiency increases cancer risk is
not clear, it has been demonstrated to alter both DNA damage and DNA
methylation. Folate deficiency has been shown to induce damage repaired via
BER pathway (80). Based on this fact, we were interested in determining what
impact folate deficiency would have on a BER deficient model. First, we needed
to confirm folate deficiency as an inducer of ACF when wildtype mice are
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subjected to a carcinogenic environment. Others, such as Branda et al. (82) have
demonstrated that folate deficient animals are less able to repair damages
induced by alkylating agents. For example, ENU was found to be more
mutagenic within the context of folate deficiency. Interestingly, folate deficiency
did not enhance the mutagenic effect of cyclophosphamide suggesting a lack of
sensitivity to lesions repaired by the nucleotide excision repair pathway. As well,
Duthie et al. (85) have further shown that human colon epithelial cells grown in
the absence of folate are poorly able to repair damages induced by MMS (an
alkylating agent) and hydrogen peroxide (an oxidizing agent). Growth in a low
folate medium has also been shown to impair excision repair capacity of
colonocytes (86). More oxidative damage, which is repaired by BER,
accumulates in response to amyloid β-peptide in neuronal cells depleted of folate
(87). In line with these studies, we show an increased incidence of ACF,
microscopic adenoma and liver tumor formation in wildtype mice upon DMH
treatment, when folate is deficient. These data indicate, in conjunction with our
previous studies (80), that the pathway responsible for repairing these damages
may be ineffective when folate is limiting. Based on the above findings, it is
inviting to suggest that folate deficiency mimics BER deficiency perhaps by
overwhelming the capacity of BER through inhibition of its rate determining
enzyme, DNA polymerase β. In other words, we suggest that the inability to
induce β-pol results in a functional BER deficiency, providing a logical
explanation for the phenotype induced by folate deficiency. That is, if folate
deficiency exerts its effects by inhibiting BER then the phenotype of folate
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deficiency should mimic that of BER deficiency, as shown in our previous studies
(80).
To address whether an underlying BER deficiency would exacerbate the
effects of folate deficiency, we subjected β-pol haploinsufficient mice to folate
deficiency. We have recently reported that aging and β-pol deficiency interact to
accelerate the development of malignant lymphomas and adenocarcinoma and
increases tumor bearing load in mice. We anticipated that folate deficiency and
BER deficiency will likewise interact to accelerate ACF formation and tumor
development in β-pol haploinsufficient animals. As expected, folate deficiency
resulted in a significant increase in ACF formation in wildtype animals exposed to
DMH, however folate deficiency reduced development of ACF in β-pol
haploinsufficient mice. Interestingly, prolonged feeding of the folate deficient diet
resulted in advanced ACF formation, microscopic adenoma and liver tumors in
wildtype mice, while β-pol haploinsufficiency attenuated onset and progression of
ACF to microscopic adenoma and prevented liver tumorgenesis. These findings
are rather exciting because folate deficiency appears to provide protection
against tumorigenesis in a BER deficient environment in all tissues where DMH
exert its damage.
To enhance our understanding of the dynamics contributing to a reduction
in ACF formation and liver tumorogenicity we conducted microarray analyses on
colon mucosa of β-pol haploinsufficient and wildtype mice in both a folate
adequate and folate deficient environment. Microarray analysis from our study
produced a list of up and down regulated genes, which were classified by their
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gene ontologies. The data show a distinctly compromised DNA repair capacity

(expression of over 100 genes are downregulated), including, but not restricted to
+/-

BER, NER and MMR, in FD β-pol

with DMH treatment. As previously

mentioned, BER is responsible for the removal of endogenous alkylation,
oxidized bases and uracil. Here we see a decrease in glycosylase, APEX, β-pol,
and ligase activity in FD DMH treated β-pol haploinsufficient mucosal tissue. In
addition to BER, NER which is responsible for the repair of bulky distortions in
DNA and MMR, which is accountable for the maintenance of normal Watson
Crick base pairing are also impaired. Findings from FD WT DMH treated mice
showed a significant upregulation in UNG, APEX, and ligase 1 activity, with a
significant downregulation in β-pol. These aforementioned findings are in line
with our previous studies (80), demonstrating FD ability to impair BER capacity.
We were also interested in the FK506 binding protein 12-rapamycin
associated protein 1 (FRAP1), also known as mTOR, for it is activated in various
types of neoplastic disease (132), and its inhibition makes cancer cells more
sensitive to chemotherapeutic agents (133). FRAP1 is a central controller of cell
proliferation, cell growth, and cell survival, becoming impaired in response to
DNA damage and nutrient withdrawal (134). Relative to our study, we see that
either damage as a result of a BER deficiency or deprivation of folate enhances
cell survival as depicted by increased incidence of ACF and tumor formation.
Fujishita et al. (135), however, have shown that inhibition of the mTOR pathway
suppresses the formation of intestinal polyps and death rates in Apc min mice.
As well, Shen et al. (136), showed in their study utilizing yeast cells, that the
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inhibition of FRAP1 through TORC1 complex by rapamycin, enhanced the
sensitivity to MMS treatment, resulting in increased cell death. Interestingly, we
show a significant downregulation in FRAP1, in FD DMH βpol haploinsufficiency.
These findings are similar to that of Fujishita (135) and Shen (136), although
here we show FD inhibiting an already BER deficient environment, suggesting a
likeness of rapamycin inhibiting TORC 1 complex and as such, enhances the
lethality of DMH. We suggest, therefore, that the downregulation of FRAP1 in the
FD DMH β-pol haploinsufficient mouse model could account for the reduced
incidence of ACF and tumor formation.
Observing the lack of response in DNA repair and reduction in FRAP1, we
studied the expression of apoptotic gene on our microarrays to determine if cell
death may be responsible for tending of imposed damage and thus reducing the
level of ACF and tumor formation. Notably, there was an upregulation of 75
differentially expressed genes related to apoptotic activity. There was an
upregulation in intrinsic/extrinsic apoptotic, and TNF signaling, as well as cell
cycle arrest in β-pol haploinsufficient mice. Interestingly, we see a reduction in
ATM, ATR and CHK2, which phosphorylate p53, rendering it active, however, a
significant increase in p21 expression, a collective inhibitor of cell cycle
progression, is detected (137). Both, CASP11, which is tightly regulated at the
transcription level, and known to regulate both apoptosis and inflammation (138),
and CASP8, an initiator of apoptosis (139) are elevated in β-pol haploinsufficient
mice in a folate deficient environment. In addition, we see a highly significant up
regulation in GAS1, a known tumor suppressor (140, 141) that mediates cell
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cycle arrest and apoptosis (142, 143, 144, 145). Based on our results, we would
suggest that colon cells in DMH treated β-pol haploinsufficient mice in a folate
deficient environment would prefer to undergo cell death, rather than attempt
repair. Interestingly, a distinct upregulation in PARP 3, 4, 8, 12 and 14
expression in FD, DMH treated β-pol haploinsufficient colonic mucosa is
observed. In addition to mediating BER by recruiting BER intermediates like βpol, PARPs are the key regulators of cell survival and cell death (146). As well,
-/-

Huang et al. (147), in their study utilizing Bax Bak

-/-

mouse embryonic

fibroblasts, show depletion in ATP secondary to PARP-1 activation, which in turn
inhibits FRAP1. We suggest that down regulation in expression of key enzymes
in BER pathway, e.g., UNG, β-pol and APE1, Lig1 and XRCC1, renders available
PARPs futile. In other words, elevation in PARPS would result in depletion of
ATP/NAD(+) levels and subsequent down regulation in FRAP1/mTOR pathway.
Moreover, cleavage of PARPs by CASP3 (148) triggers apoptosis and induces
cell death. Interestingly, while FD WT DMH treated animals show a significant
decline in the level of CASP3, a key “executioner” of apoptosis (149). It should be
noted that the activity in FD WT counterparts show either no change in
differential expression or slight opposing expression of both apoptotic and DNA
repair genes. These findings provide further evidence of defense by BER
deficiency in the multi-step process of colon/liver cancer, when folate is deficient.
We propose that β-pol deficiency in a folate deficient environment results
in increased accumulation of DNA repair intermediates that impacts the balance
between cell survival and cell death, pushing cells toward apoptosis, thus
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reducing onset and progression of preneoplastic lesions. In support of this notion,
we provide evidence that the β-pol haploinsufficient mice fed a folate deficient
diet display increased apoptotic body and decreased proliferation in their colon in
response to DMH. Interestingly, in agreement with our findings,
Ochs et al (150) demonstrated that BER deficiency results in the accumulation of
repair intermediates, along with increased DSB in β-pol null fibroblasts exposed
to the alkylating agent, MMS. Interestingly, accumulation of DNA damage in
these cells resulted in decline in Bcl-2 and increased Caspase 3/9 activation
triggering apoptosis in a replication dependent manner. Moreover, Taverna et al
(151) showed that BER inhibition by methoxyamine increased cytotoxicity of the
methylating agent temozolomide through persistence in AP sites, increased DSB
and increased apoptosis in HCT 116 colon cancer cell lines. Likewise, Rinne et
al. (152) showed that breast cancer cell lines overexpressing N-methylpurine
DNA

glycosylase

methanesulfonate,

(MPG)

exposed

to

the

alkylating

N-methyl-N'-nitro-N-nitrosoguanidine,

agents

methyl

methylnitrosourea,

dimethyl sulfate, and the clinical chemotherapeutic temozolomide, significantly
increases the sensitivity of these cells. Sensitivity is further increased through
coadministration of the BER inhibitor methoxyamine making cells unable to
complete repair initiated by the glycosylase, and resulting in an increase in the
number of AP sites and SSBs. Furthermore, Fishel et al. (153) showed that
overexpression of MPG, in addition to inhibition of BER pathway via
methoxyamine, dramatically increases the sensitivity of ovarian cancer cells to
the DNA methylating agent temozolomide via increase in apoptotic activity. In
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6

3

other words, methylation of N and O positions of guanine and the N of adenine by
temozolomide, in addition to overexpression of MPG, resulted in initiation of

BER. However, inhibition of BER pathway by methoxyamine downstream of
glycosylase resulted in an accumulation of DNA repair intermediate, increased
DNA DSB and triggered apoptosis in a p53 independent manner. Furthermore,
Trivedi et al. (154) showed that elevated MPG expression in addition to β-pol
knockdown would result in increased sensitivity of human breast cancer cells to
temozolomide. Interestingly, Trivedi et al (154) showed that overexpression of
β-pol with mutation in its polymerase site, while maintaining it dRP lyase activity,
resulted in restoration of resistance to temozolomide in β-pol knockdown human
breast cancer cell lines.
The in vitro studies outlined above utilize specific glycosylases for the
creation and persistence of abasic sites, while, methoxyamine potentiates the
cytotoxicity of telozolomide through its binding to abasic sites, hampering BER,
resulting in accumulation of repair intermediates and ultimately, DNA DSBs.
These conditions generate a perfect environment for apoptosis to take place.
These studies add to the fascination of our own, for the aforementioned were
conducted within cell lines, whereas, our in vivo data demonstrate protection
against actual onset and progression of tumor, via similar mechanism. Our data
shows that treatment of mice with DMH results in damage to bases, along with
upregulation in UNG expression/activity (data not shown), that when combined
with βpol haploinsufficiency, results in an accumulation of DNA repair
intermediates and ultimately DNA DSBs, resulting in the onset of ACF,
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progression of microadenoma and tumors, in colon and liver, respectively. We
suggest that wildtype animals fed a folate deficient diet and subject to DMH
treatment exhibit a similar scenario. In other words, folate deficiency and DMH
treatment would result in the induction of DNA damage, upregulation in specific
glycosylases, and downregulation in BER capacity all of which contribute to an
accumulation of repair intermediates that create an environment favoring tumor
formation. In contrast, BER haploinsufficiency combined with folate deficiency
provide a protective environment against DMH carcinogenesis. Thus, folate
deficiency sensitizes the β-pol haploinsufficient mice to DMH, generating even
higher level of DNA SSBs and DSBs, mimicking the environment observed in invitro studies. These conditions are favorable to apoptosis, where DNA repair
machineries are downregulated and proapoptotic pathways are induced.
In line with our findings, Lawrance et al. (155) showed that folate

deficiency in mthfr deficient Apc

min/+

mice results in a reduction in adenoma

formation in colon tissue, while an elevation in dUTP/dTTP ratio in DNA and an
increase in apoptotic activity are observed. APC has been shown to interact with
β-pol (156). Furthermore, haploinsufficiency in reduced-folate carrier gene

(Rfc

+/-

) creating a folate deficiency phenotype resulted in decreased adenomas
min/+

and tumor load in Apc

mice. In addition, Branda et al (157) showed folate

deficiency reduced mutation frequency in 3-methyladenine glycosylase null mice
exposed to methyl methanesulfonate. The aforementioned, demonstrate much
the same as our investigation in that modulating BER repair, through β-pol and
exposure to folate deficiency, results in reduced repair activity while influencing
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apoptosis. Additionally, research conducted by Duthie et al. (158), demonstrated
that NCM460 immortalized cells in a folate deficient media exposed to hydrogen
peroxide exhibit increased apoptotic activity, as well as, decreased proliferation.
Furthermore, Crott et al. (159) showed an inverse correlation between
expression of genes involved in cell cycle checkpoint and media folate levels (25
to 100nM) in NCM460, HCEC and NCM356 cell lines derived from human colon,
irrespective of oxidative stress. These studies, much like our own, have
significantly reduced levels of folate, rather than a complete folate deficit. In our
experiments, despite use of a folate deficient diet and use of succinyl
sulfathiazole, an 80 – 90% reduction in folate levels is observed relative to folate
adequate diets. It is at this reduced level that we see protective effects.
In conclusion, our data indicate BER deficiency and DMH treatment
interact synergistically to increase DNA repair intermediates and genomic
instability, resulting in formation of preneoplastic lesions, while folate deficiency
in BER deficient mice exposed to DMH provides protection, creating an
environment preferential to apoptosis. While folate deficiency induces DNA
damage in control/untreated mice (80), slight upregulation in DNA repair activity
and maintaining normal or slightly lower levels of apoptotic activity prevents
onset of tumorigenesis. In contrast, folate deficiency in response to DNA
damaging agent would result in accumulation of genotoxic intermediates that are
potentially mutagenic and thus, as shown here, prone to increased ACF and
tumor formation. However, when a BER deficiency is present and subject to
exposure of DMH, induction of a folate deficient environment results in a further
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reduction of DNA repair capacity and increased level of apoptosis. This is
suggestive that the damage is so extensive that is beyond repair, thus opting for
cell death. We surmise that the damage induced blocks BER capacity, resulting
in elevated PARP levels, which in turn deplete energy availability to the cell,
signalling need for cell death. These conditions result in a reduction of ACF and
tumor formation. This study has great therapeutic importance and human
relevance as recent findings indicate BER inhibitors in combination with the DNA
methylating agent temozolomide, function as an effective chemopreventive agent
in colon cancer (160). In addition, these findings have relevant translational
implications, since variants/polymorphisms in BER has been associated with
increased cancer risk, and an alteration in micronutrients could potentially
provide protections under the right conditions.
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CHAPTER 4
Microarray Gene Expression Profiling of Dietary Folate Deficiency on Colon
Carcinogenesis in DNA Polymerase ββ Haploinsufficient Mice

Introduction
Colorectal cancer is one of the most prevalent and lethal types of
malignancies in Western countries and represents the second leading cause of
cancer death in the US (161). It has been implicated that environmental factors
relative to a Western lifestyle are responsible for this intestinal neoplastic
transformation. Much research has focused on the strong connection between
the carcinogenic properties of folate deficiency and increased colon cancer risk
(162). It has been proposed that folate deficiency imparts high levels of uracil and
oxidative damage to the DNA that may increase the risk of atypical DNA
methylation, high levels of uracil misincorporation in DNA, and increased levels
of DNA single strand breaks. Folate has also been shown to increase
micronucleus formation and chromosomal aberrations all leading to increased
mutational frequency and colon cancer progression.
It is well documented that the Base Excision Repair (BER) pathway is
responsible for the removal of uracil and oxidized bases throughout the cell
cycle. Its primary obligation is believed to be the repair of small, non-helix
distorted lesions in the DNA. If damaged bases are left unrepaired it could cause
mutations via mispairing and/or strand breaks in DNA during replication. Briefly,
the removal of damaged bases by BER involves i) a specific DNA glycosylase
binding to the affected base and hydrolyzing the N-glycosidic bond, releasing the
damaged base while keeping the DNA backbone intact. ii) The abasic site is
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subsequently recognized by an endonuclease, notably Ape 1, which nicks the
phosphodiester backbone immediately 5’ to the lesion leaving a strand break with
a normal 3’-hydroxyl group and an abnormal 5’dRp residue. iii) synthesis of new
DNA by incorporation of the correct nucleotide by DNA polymerase, iv) excision
of the 5’dRp moiety, and v) ligation by a DNA ligase (Ligase 1 or Ligase
3/XCRR1 (127). Short patch BER is the major repair mode, where β-pol performs
the polymerization steps and appears to be the rate-limiting step by virtue of its
dRp lyase activity (53). With the removal of damaged bases, as would occur with
uracil misincorporation, and repair of abasic sites, a transient formation of a DNA
single strand break occurs. We have previously shown that
+/-

β-pol

results in genomic instability as a result of persistence of these DNA

single strand breaks which could result in DNA double stand breaks (60).
Additionally, in response to alkylating and oxidizing agents, these animals display
accelerated age-related tumor development such as lymphomas, which are
atypical of C57BL/mice (77).
The β-pol haploinsufficient mouse has been shown to have a reduced
ability to tolerate carcinogen exposure, demonstrating reduced BER capacity and
this translates into concern regarding the development of certain cancers. In
fact, mutations in the gene encoding β-pol have been previously identified in
human colorectal, prostate, lung and breast carcinomas (68, 69, 70, 71). These
mutations are found only in the tumor tissue and not in the adjacent normal
tissue, thus corresponding to sporadic mutations (73). Based on these findings
and our previous reports of β-pol haploinsufficiency on DNA (60), it would seem
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prudent to assume that the high levels of uracil misincorporated into the DNA
backbone, as a result of inadequate folate levels, would lead to an increase
insingle strand breaks as a result of β-pol deficiency, overwhelming BER,
proceeding to mutagenesis. Centered on these experimental findings, in our
+/-

study of β-pol

in a folate deficient environment, we expected that β-pol

haploinsufficiency would result in extreme damage with a dramatic increase in
the formation of the first histologically detectable change apparent in colon
cancer, the aberrant crypt and potentially progressive colon cancer development.
Astoundingly, we saw not only significantly less ACF development but
additionally, those that did form were visually less advanced than wildtype mice
exposed to 1,2 dimethylhydrazine (DMH) a known colon and liver carcinogen. As
well, we saw no detectable pathological changes in liver tissue as noted in the
wildtype folate deficient mice subject to DMH (Figure 5B). Based on our
remarkable findings, the purpose of this study was to determine the potential
mechanism behind the protective effect β-pol haploinsufficiency appears to
confer with respect to colon cancer development in response to folate deficiency
and DMH. Microarray technology has made accessible a powerful tool for
identifying possible means of the effect of folate and DMH on the onset and
progression of colon cancer in the colonic mucosa of β-pol haploinsufficient mice
at the level of the transcriptome. These findings are invaluable for they offer
direction, through pinpointing potential means of this disease, necessary for
further studies.
Methods
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Animals. Experiments were performed in young 4 to 6 month old
C57BL/6-specific pathogen free male mice and mice heterozygous for the DNA
+/-

polymerase β gene (β-pol

) (77). All practices performed on animals were in

agreement with the National Institutes of Health (NIH) guidelines for the care and
use of laboratory animals. Mice were backcrossed to the C57BL/6 background.
The Wayne State University Animal Investigation Committee approved the
animal protocol. Mice were maintained on a 12-h light/dark cycle and given water
ad libitum.
Diets and Carcinogenic Treatment.
+/-

wildtype (WT) and β-pol

After acclimation for 7 days,

mice were randomly assigned to two dietary groups; a

folate adequate (FA) or folate deficient (FD) AIN93G-purified isoenergetic diet
(Dyets, Inc., Lehigh Valley, PA) as described previously (80). The FA group
received a folate adequate diet containing 2 mg/kg folic acid. The FD group
received a folate-deficient diet containing 0 mg/kg folic acid. Diets were stored at
–20°C. 1% succinyl sulfathiazole was added to all diets . One week after
commencement of food ingestion, randomly selected mice from both FA and FD
were injected i.p. with 1,2-Dimethylhydrazine HCL (DMH, 30 mg/kg body weight)
in 10mmol/L of NaHCO3 (Fisher Scientific, Fair Lawn, NJ) once a week for 6 wks
(Figure2, panel A). Both food intake and body weights were checked twice
weekly to monitor for signs of of toxicity, e.g., weight loss, and the diets were
continued for 12 weeks.
Microarray assays. Total RNAs were isolated from the colon mucosa of
mice using the RNeasy Mini Kit (Qiagen, Valencia, CA) per manufacturer's
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protocol.

RNA samples were quantified with NanoDrop ND-1000 (NanoDrop

Technologies, Inc, Wilmington, DE) and 260/280 ratio in the range of 2.0-2.2 was
defined as acceptable. A quality check of the total RNA was performed using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). One micro liter of
total RNA sample was applied on RNA 6000 NanoChip, and the assay was run
on the Bioanalyzer to determine if the 18S and 28S ribosomal bands are defined
and to ensure no RNA degradation was present. Optimal concentration used to
check the RNA quality is 250ng/∝
∝l.
Microarray expression profiling was conducted by Microarray &
Bioinformatics Facility Core at Wayne State University (Institute of Environmental
Health Sciences, Detroit, MI) according to the manufacturer’s protocol. A
balanced block experimental design was used: 4 microarrays were completed for
each comparison, with each microarray representing 1 randomly selected labeled
mucosal sample from each experimental group paired with 1 randomly selected
FA WT labeled mucosal sample i.e. in total 4 mucosal RNA samples from FDWT
cohybridized with 4 FAWT, 4 FDWT DMH treated cohybridized with 4 FAWT and
+/-

4 FD β-pol

DMH cohybridized with 4 FAWT treated, representing 4 micorarrays for

each experimental comparison. Samples on a given array were oppositely labeled
with Alexa 647 and Alexa 555 dyes. The four microarrays for a given
+/-

group (i.e., WT untreated, WT DMH or β-pol

DMH treated) represent samples

from eight separate mice, providing consideration of biological variation. In total,
+/-

12 arrays representing 24 mice (8 WT, 8 WT DMH-treated, 8 β-pol

DMH-

treated) were completed. Dye swaps were used to account for dye bias effects
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such that of the four arrays in a given phenotype group, two had FD treated
samples labeled with Alexa 647 co-hybridized with control samples labeled with
Alexa 555 while the other two arrays within the same phenotype group had
opposite dye orientations. Microarrays were scanned using the Agilent dual laser
DNA micorarray scanner model G2565AA, with 10 micron resolution.
Microarray gene profile analysis. Microarray image analysis was
performed with Agilent Feature Extraction software, version A.5.1.1. Hierarchal
Clustering

analysis

was

performed

using

GeneSpringGX

V10

(Agilent

Technologies) software, and the parameters were set for centroid linkage which
calculates the euclidean distance between the respective centroids of two
clusters. Heatmaps were created by inputting accession numbers of differentially
+/-

expressed genes, at p<0.001, for FDWT and FD β-pol

DMH-treated

experimental groups through DAVID functional annotation. Outputs revealed
gene onotologies of differentially expressed genes, which were than compared to
created differentially expressed gene lists of DAVID biological processes, such
as apoptosis and DNA repair. Data sets were then combined for FDWT and FD
+/-

β-pol

DMH-treated to 1 large data set in order to create heatmaps for each

biological function. Gene ontology analysis was performed using Gene Ontology
Tree

Machine

(GOTM),

(Bioinformatics,Vanderbilt

University),

applying

differentially expressed genes as depicted in the heatmaps`. We chose a single
gene set analysis, where GOTM compares the distribution of single gene set in
each GO category to those in an existing reference gene list from the mouse
genome, identifying GO categories with statistically significant enriched gene
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numbers as determined by the hypergeometric test (p<0.01) (119, 120). Real
time quantitative RT-PCR was used to confirm the data obtained for selected
genes in DNA repair pathways as described above.
Results
Experimental design
To elicit the role that folate plays in the onset of colon carcinogenesis in a
+/-

BER deficient environment, wildtype and β-pol

animals were fed either a folate

adequate (FA, 2 mg/kg folic acid) or a folate deficient (FD, 0 mg/kg folic acid) diet
as outlined in Figure 2A. To induce severe folate deficiency, 1% Succinyl
Sulfathiazole was added to the diet deficient in folic acid to prevent synthesis of
folic acid in the gut by bacteria. The animals’ food intake and body weight were
monitored weekly. Folate deficiency did not affect body weight while it reduced
the plasma folate level by 90% as determined by a SimulTRAC-SNB radioassay
57

kit for vitamin B12 ( Co) and folate (

125

I) per the manufacturer's protocol (ICN

Diagnostics, Orangeburg, NY) as described previously (80). After one week on
respective diet randomly selected mice from each feeding study were injected
with 30mg/kg body weight DMH once per week for 6 weeks (Figure 2A). We
chose DMH as it is a known colon and liver carcinogen that gets converted to the
active metabolites azoxymethane and methylazoxymethanol in the liver, which
are then transported to the colon via blood and bile (125). Once in the tissues
DMH induces alkylation (O6-meG and N7-meG) as well as oxidative damage
impairing DNA. Although direct reversal is responsible for the repair of 06-meG,
we have previously shown that the BER pathway processes N7-meG lesions
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(60). Six weeks after the final injection DMH-treated and control mice were
sacrificed. Mucosal scrapings were taken and used to perform a balanced block
experimental microarray design to screen for differentially expressed genes in
response to folate deficiency (FD) and 1,2- dimethylhydrazine (DMH) mice.
Microarray gene expression analysis
Our previous studies determined an increased level of ACF, increased cell
proliferation, as depicted by BrdU analysis and a decrease in apoptotic activity,
shown by the TUNEL assay, in wildtype mice exposed to DMH in a folate
+/-

deficient environment. In contrast, FD DMH β-pol

treated mice showed

decreased formation of ACF, reduced proliferative capacity and an increase in
the level of apoptosis (163). We wanted to know, therefore, the effect of folate
and DMH on gene expression. In order to do so, we categorized genes according
to their biological function as depicted through DAVID biological processes.

Gene Expression analysis of folate pathway
Knowing folates suggested role in colon carcinogenesis, we initially
analyzed microarray gene expression data with respect to folate and its
5

10

metabolism (Table VI). Here we see a down regulation in N , N

methylene

tetrahydrfolate reductase (MTHFR), an enzyme which reduces 5, 10methylenetetrahydrofolate to 5-methyltetrahydrofolate using NAD(P)H as the
+/-

reducing agent, in FA DMH, FD DMH treated and FD β-pol

DMH treated mice.

As well, we see an upregulation of dihydrofolate reductase (DHFR), which
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reduces dihydrofolic acid to tetrahydrofolic acid, using NADPH as electron donor,
in FDWT, FA DMH, and FD DMH treated colonic mucosa, however it is
+/-

significantly downregulated in FD β-pol

DMH treated mice. Interestingly, we

also see an increase in thymidylate synthase (TS), an enzyme which converts
dUMP to dTMP, in FD DMH treated animals and no change in FD WT or FA WT
+/-

DMH treated mice, whereas FD β-pol

DMH treated mice show a significant

downregulation. Correspondingly, there is a significant downregulation in
dUTPase (5031412I06Rik) in β-pol haploinsufficiency which is either upregulated
or not differentially expressed in other animal models. This indicates a lack of
+/-

pyrimidine synthesis in FD β-pol

with DMH treatment, in contrast to the other

experimental models which are still capable of producing thymidine. From these
findings one could conclude that availability of purines and pyrimidines would be
significantly lowered in the β-pol haploinsufficient mouse when subject to DMH
and a folate deficit. These results shed light on our previous findings of reduced
+/-

DNA repair capacity in FD β-pol

DMH treated mice.

Gene Expression analysis of DNA repair genes
Both FD DMH and FA DMH treated mice showed a 75% elevation in DNA
repair expression (44 upregulated and 15 downregulated, 33 upregulated and 11
downregulated, respectively), whereas FD untreated animals demonstrated an
84% elevation (31 upregulated and 6 downregulated) in repair activity.
Interestingly, FD β-pol

+/-

DMH treated mice shows an 88% reduction in DNA

repair activity (13 upregulated and 92 downregulated). These findings indicate
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sufficient levels of purines and pyrimidines for DNA repair in FDWT, FA DMH,
and FD DMH treated mice, however, deficiency in these nitrogenous bases
+/-

appears to hamper DNA repair in FD β-pol

DMH treated mice. It should be

noted that genes expressed in any experimental model are characteristically, but
not exclusively related to BER. NER, MMR NHEJ and recombination repair
(Table VII). Denoting the reduced capacity in repair, determining repair
machineries access to chromatin is important, for this access is needed in order
for repair to proceed.
Gene expression analysis of histones
Noting the differential expression of DNA repair genes in all animal models
studied, we wanted to know the impact of a BER deficiency on histone
modification when folate is deficient, for it is the histones that unpackage the
DNA in order for damage recognition. Chromatin remodeling allows for changes
in histone-DNA interactions in the nucleosome. This is achieved by the action of
chromatin-remodeling complexes, which are a family of ATP-dependent
machines that participate in transcriptional regulation, DNA repair, and chromatin
assembly. (164). Gene expression of these family subunits are significantly
+/-

downregulated in FD β-pol

DMH treated colonic mucosa, but show no

differential expression in FD WT, FA WT DMH, and FD WT DMH treated mice
(Table VIII). Our microarray analysis also shows a significant reduction in genes
related to histone H2A, one of the core components of the nucleosome, in FD β+/-

pol

DMH treated mice, whereas all other experimental groups showed no

change in expression of H2A with the exception of one varied gene being
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downregulated in each of the groups. Of particular interest is H2AX , for it is a
receptive target for looking at DSBs in the cell. Once phosphorylated, H2AX
lessens DNA condensation and increasing its availability for recruitment of repair
machinery to DSBs (165). We have previously ascertained an increase in SSB in
β-pol haploinsufficiency exposed to a folate deficit (80). If these SSB are not
properly repaired, they may result in double strand breaks (DSB) in replicating
DNA. DSB recognition involves activation of ATM which functions to control the
rate at which cells grow. In turn, ATM phosphorylates H2afx. Both ATM (Table
VII) and H2AFX are significantly downregulated in FD β-pol haploinsufficiency
with i.p DMH treatment. All other experimental groups showed no difference in
expression of these aforementioned genes. Although phosphorylation of H2AX is
most dependent on ATM, phosphorylation can also be carried out via ATR
(Table VII) and PRKDC (also known as DNA-pk)(Table VII) (165, 166, 167, 168)
Both of these aforementioned genes are instrumental in NHEJ and HR, pathways
+/-

that are significantly downregulated in FD β-pol

DMH treated mice, whereas

they are either increased or not significantly different in FD WT, FA WT DMH,
and FD WT DMH treated mice. These findings are suggestive of chromatin
condensation an event which would favor apoptotic activity (169).
Gene expression analysis apoptotic activity
Based on our previous findings of apoptotic activity depicted by TUNEL
assay (Figure 8A), we wanted to know the apoptotic gene expression of all
experimental models. We saw a 51% upregulation (22 upregulated and 21
downregulated) in proapoptotic activity in FD DMH treated mice and 57% (69
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+/-

upregulated and 53 downregulated) in FD β-pol

treated mice in contrast to FD

WT untreated (70% reduction, 9 upregulated and 21 downregulated) and FA WT
DMH treated (49% reduction, 19 upregulated and 20 downregulated). There was
a 59% decline (15 upregulated and 19 downregulated), 67% decline (9
upregulated and 18 downregulated), 71% decline (11 upregulated and 27
downregulated) and 52% decline (23 upregulated and 25 downregulated) in
+/-

antiapoptotic genes in FD WT DMH, FD untreated, FA WT DMH and β-pol

treated mice, respectively. Although apoptotic levels are inclined in FD WT DMH
treated, CASP3, which is downstream in the apoptotic pathway, is significantly
+/-

downregulated, whereas it is significantly upregulated in FD β-pol

DMH treated

and unchanged in FD WT untreated or FA WT DMH treated mice (Table IX).
Noting lack of DNA repair activity and elevation of apoptosis, specifically CASP3
+/-

in FD β-pol

DMH treated mice; we wanted to determine the impact of PARP

activity on colonic mucosa.
Gene expression analysis of poly(ADP-ribose) polymerase (PARP)
We wanted to know the level of PARP activity as it plays a vital role in

DNA repair and programmed cell death.

The most widely studied PARP is

PARP1, which is activated mainly by SSBs or DSBs (170). Inhibition of PARP
enzyme activity interferes with DNA base excision repair and leads to increased
genetic instability and recombination but, on the other hand, can sensitize cells to
apoptotic stimuli and by this mechanism may prevent tumor formation. While FD
untreated mice show reduced or unchanged PARP expression, WT FD DMH
mice display increased levels, specifically PARP1 and PARP3, which associates
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with components of BER and NHEJ (171) or no change in gene expression and
FA WT DMH as well, show elevated levels of PARP1 or no significant change, as
+/-

did FD β-pol

DMH treated mice with the exception of PARP1 which is

downregulated (Table X). When PARPs become elevated they signal for
apoptosis or necrosis, which then becomes cleaved by CASP3 in order to
prevent depletion of NAD. In this current study their is a reduction in PARP1 in
+/

FD β-pol - DMH treated mice and it appears as though the reduction in PARP1
maybe related to its cleavage by CASP3. While PARP1 levels are elevated in
both FD WT DMH and FA WT DMH treated mice CASP3 is either downregulated
or unchanged in these animal models, respectively (Table IX). We suggest that
+/

the level of cellular toxicity imposed by FD β-pol - DMH treated mice causes a
significant reduction in ATP levels hence the signaling for PARP1 cleavage by
CASP3.
Gene expression analysis of energy sensors
Noting a reduction in ATP dependent chromatin remodeling machinery,
DNA repair and PARP, as well as an increase in apoptotic activity, we wanted to
know the impact of β-pol haploinsufficiency on energy sensing gene expression.
Microarray analysis demonstrates a significant upregulation in energy sensing
enzymes Cab39 (aka MO25), a scaffold protein that activates Stk11 (aka LKB1),
and Stk11, a tumor suppressor kinase that phosphorylates and activates AMPactivated protein kinase (AMPK) when cellular energy levels are low (172), in FD
+/-

β-pol

treated mice (Table XI). In addition, Prkab1 (aka AMPK), which inhibits

cell growth and proliferation through multiple pathways (172) is significantly
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+/-

elevated in FD β-pol

treated mice. This information provides confirmation of

energetic stress, consequently resulting in inhibition of cell survival and support
of cell death. In view of these findings we wanted to look at the gene expression
of downstream targets of AMPK that either produce ATP or consume it.
Differential expression of genes in downstream events of AMPK
Based on significant upregulation in expression of genes related to energy
+/-

sensing, we wanted to know the impact of FD β-pol

DMH treatment on ATP-

producing versus ATP-consuming processes. Interestingly, we see a significant
upregulation in expression of genes related to glucose uptake (GLUT4),
glycolysis (Pfkfb3), and mitochondrial biogenesis (Ppargc1), all of which result in
ATP-producing catabolic processes. In contrast, we see a downregulation in
gene expression of enzymes involved in fatty acid synthesis (Acaca), sterol
synthesis (Hmgcr), glycogen synthesis (Gys2) and protein synthesis (FRAP1),
indicating a downregulation in ATP-consuming processes (Table XI). These
findings suggest that amidst energy deprivation, cells react to try and conserve
ATP. With the aforementioned, we decided to analyze gene expression levels
related to the cell cycle pathway.
Expression analysis of cell cycle related genes
Knowing the differential expression apoptotic capacity in all animal
models, we decided to study the effects of FD and DMH on cell cycle pathway
gene expression to gather a further understanding of the series of events that
take place in the cell leading to cell division and replication. We see relative little
difference in gene expression related to cell cycle progression in FD DMH (67%
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increase, 24 upregulated and 12 downregulated), FD untreated (65% increase,
25 upregulated and 13 downregulated) and FA DMH (68% increase, 32
+/-

upregulated and 15 downregulated), respectively). Conversely, FD β-pol

treated mice show a 65% downregulation in expression of genes related to cell
cycle progression.(18 upregulated and 33 downregulated). Of interest, Cdk4
which is important for cell cycle G1 phase progression and Cdk 6 for both
progression and G1/S transition, cyclin E1, which forms a complex with cdk2 also
+/-

for cell cycle G1/S transition, are all significantly downregulated in FD β-pol

treated mice (Table XII). These cell cycle dependent genes are either
significantly upregulated or not differentially expressed in all other experimental
conditions. Additionally, we see a significant reduction in expression of genes
related to cell cycle arrest in FD untreated (52%, 10 upregulated and 11
downregulated), FD DMH treated mice (52%, 10 upregulated and 11
+/-

downregulated) and FD β-pol

treated (55%, 13 upregulated and 16

downregulated), whereas, FA DMH treated (55%, 17 upregulated and 14
downregulated) shows significant increases in genes related to cell cycle arrest.
Although genes related to cell cycle arrest are downregulated, it should be noted
that P15 which forms a complex with Cdk4 or Cdk6, and prevents the activation
of the Cdk kinases, p21 which binds to and inhibits the activity of cyclin-Cdk2 or Cdk4 complexes, p27, which binds to and prevents the activation of cyclin E+/-

Cdk2 or cyclin D-Cdk4 complexes, are all downregulated in FD β-pol

treated

mice (Table XII). All function as cell growth regulators that control cell cycle
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G1/S progression. Having discovered all of these findings, we wanted to know

the expression of key genes related to the colorectal cancer pathway
Gene expression analysis of genes related to colorectal cancer pathway
Using DAVID bioinformatics we looked at the colorectal cancer pathway
+/-

gene expression. Interestingly, FD β-pol

DMH treated mice showed a

decreased expression of genes downstream where these genes confer upon
either proliferation or antiapoptotic activity. In particular, there is reduced
expression of myc, which mediates the cellular response to growth factors and
survivin, a member of the inhibitor of apoptosis, in β-pol haploinsufficiency
exposed to DMH in a folate deficient environment. These genes are significantly
upregulated or not differentially expressed in FDWT, FAWT DMH, and FDWT
DMH (Table XIII).
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Table VI. Summary of the effect of folate deficiency on folate pathway genes in wildtype, wildtypeDMH+/treated and β-pol DMH-treated mice*

Accession no.

Gene name

NM_010840
L26316
AI323028
XM_138431
NM_023595
NM_145569
AK038303
NM_010066
NM_010067
NM_007872
NM_010068
NM_010321
BC015304

5,10-methylenetetrahydrofolate reductase
Dihydrofolate reductase
Thymidylate synthase
5-methyltetrahydrofolate-homocysteine methyltransferase
Deoxyuridine triphosphatase
Methionine adenosyltransferase II, alpha
Methionine adenosyltransferase II, beta
DNA methyltransferase (cytosine-5) 1
DNA methyltransferase 2
DNA methyltransferase 3A
DNA methyltransferase 3B
Glycine N-methyltransferase
S-adenosylhomocysteine hydrolase

* P<0.05; ns, no significant difference

FDWT FAWT FDWT
DMH DMH

ns
ns
ns
ns
ns
ns
ns
ns
-1.4
-1.2
ns
ns
ns

-1.2
1.3
ns
ns
ns
ns
ns
ns
-1.4
ns
1.5
ns
ns

-1.3
1.2
ns
ns
1.5
ns
-1.4
1.4
-1.2
-1.3
1.3
ns
ns

+/-

FDβ-pol
DMH

-1.3
-1.8
-1.9
-1.4
-1.5
1.2
1.5
-1.5
ns
ns
-1.5
3.4
-1.7
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Table VII. Summary of the effect of folate deficiency DNA pathway genes in wildtype, wildtypeDMH+/treated and β-pol DMH-treated mice*
Accession no.
NM_009764
NM_009765
AF236887
AK048970
NM_009012
NM_011236
NM_009015
NM_011677
NM_181569
NM_011561
NM_009687
AK047252
NM_021498
NM_010715
NM_010716
AK048442
NM_008628
NM_133250
NM_010829
NM_146235
NM_007949
NM_009531
NM_016926
NM_175027
NM_007985
NM_018736
NM_011045
NM_009532
NM_028875
NM_009533

Gene name
Breast Cancer 1
Breast Cancer 2
Ataxia telangiectasia and Rad3 related
Ataxia telangiectasia mutated homolog (human)
RAD50 homolog
RAD52 homolog (S. cerevisiae)
RAD54 like
Uracil DNA glycosylase
N-methylpurine-DNA glycosylase
Thymine DNA glycosylase
Apurinic/apyrimidinic endonuclease 1
Polymerase (DNA directed), beta
Polymerase (DNA directed), epsilon 3 (p17 subunit)
Ligase I, DNA, ATP-dependent
Ligase III, DNA, ATP-dependent
Ligase IV, ATP-dependent
MutS homolog 2
MutY homolog (E. coli)
MutS homolog 3
Excision repair cross-complementing complementation
group 6 - Like
Excision repair cross-complementing complementation
group 2
Xeroderma pigmentosum, complementation group C
Fanconi anemia, complementation group A
Fanconi anemia, complementation group B
Fanconi anemia, complementation group C
Meiotic recombination 11 homolog A
Proliferating cell nuclear antigen
X-ray repair complementing defective repair in Chinese
hamster cells 1
X-ray repair complementing defective repair in Chinese
hamster cells 3
X-ray repair complementing defective repair in Chinese
hamster cells 5

* P<0.05; ns, no significant difference

FDWT

FAWT FDWT
DMH DMH

FDβ-pol
DMH

1.4
1.5
1.2
ns
ns
1.3
1.4
1.2
ns
ns
ns
ns
ns
1.2
1.3
ns
1.3
ns
ns
1.3

1.5
1.4
1.3
ns
ns
ns
1.8
1.8
ns
ns
ns
-1.8
ns
1.4
1.3
ns
ns
ns
ns
1.5

ns
1.5
1.2
ns
ns
1.2
ns
1.6
ns
ns
1.4
-1.4
ns
1.5
ns
ns
1.3
1.3
ns
1.8

-1.8
-1.4
-1.3
-1.6
-1.2
-1.2
-2.0
-1.6
-1.4
-1.2
-1.7
-1.5
-1.3
-1.3
-1.3
-1.4
-1.5
-1.7
-1.4
-2.3

ns

ns

ns

-1.3

ns
1.3
1.3
ns
1.2
ns
ns

ns
1.6
1.5
ns
ns
1.3
ns

ns
1.6
ns
ns
ns
ns
ns

-1.2
-1.4
-1.6
-1.3
-1.3
-1.3
-1.2

ns

ns

ns

-1.7

ns

ns

1.2

-1.4

+/-

95

Table VIII. Summary of the effect of folate deficiency chromatin remodelling in wildtype, wildtypeDMH+/treated and β-pol DMH-treated mice*
FDWT

Accession no.

NM_053123
NM_009211
NM_146235
NM_144958
AK033272
NM_010436

Gene name
SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, subfamily a, member 1
SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, subfamily c, member 1
Excision repair cross-complementing rodent repair
deficiency complementation group 6 - like
Eukaryotic translation initiation factor 4A1
AT rich interactive domain 1B (Swi1 like)
H2A histone family, member X

* P<0.05; ns, no significant difference

FAWT FDWT
DMH DMH

+/-

FDβ-pol
DMH

ns

ns

ns

-1.5

ns

ns

-1.3

-1.5

1.3
ns
ns
ns

1.5
ns
ns
ns

1.8
ns
ns
ns

-2.3
-1.4
-1.2
-1.6
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Table IX. Summary of the effect of folate deficiency apoptosis pathway in wildtype, wildtypeDMH-treated
+/and β-pol DMH-treated mice*
Accession no.

Gene name

NM_008086
NM_011641
NM_009367
NM_008337
NM_008329
NM_009807
NM_009812
NM_007609
XM_139295
NM_175362
NM_011817
AK010701
NM_025858
NM_013693
NM_010177
NM_009425

Growth arrest specific 1
Transformation related protein 63
Transforming growth factor, beta 2
Interferon gamma
Interferon activated gene 203
Caspase 1
Caspase 8
Caspase 4, apoptosis-related cysteine peptidase
Caspase recruitment domain family, member 6
Caspase recruitment domain family, member 11
Growth arrest and DNA-damage-inducible 45 gamma
Death effector domain-containing DNA binding protein 2
Scotin gene
Tumor necrosis factor
Fas ligand (TNF superfamily, member 6)
Mus musculus tumor necrosis factor (ligand) superfamily,
member 10
Tumor necrosis factor (ligand) superfamily, member 12
Tumor necrosis factor receptor superfamily, member 21
Mus musculus tumor necrosis factor receptor superfamily,
member 26
Nur77 downstream gene 1
Caspase 3

NM_011614
NM_178589
NM_175649
NM_183322
NM_009810

* P<0.05; ns, no significant difference

FDWT

FAWT FDWT
DMH DMH

FDβ-pol
DMH

-2.9
ns
ns
ns
1.4
ns
ns
ns
ns
ns
ns
-1.2
-1.2
ns
ns
-2.4

ns
ns
ns
-3.9
2.2
ns
ns
ns
ns
1.4
ns
ns
ns
ns
ns
ns

ns
ns
ns
ns
2.3
ns
ns
1.5
ns
1.2
ns
ns
1.2
ns
3.2
ns

8.8
27.4
11.4
4.1
4.0
1.3
1.4
2.1
1.4
1.7
1.5
1.6
1.4
3.9
2.1
2.0

ns
ns
ns

ns
ns
ns

ns
ns
ns

2.2
1.4
4.1

-2.5
ns

ns
ns

3.9
-1.4

3.0
1.7

+/-
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Table X. Summary of the effect of folate deficiency on Poly (ADP-ribose) polymerase (PARP) in wildtype
and DMH treated wildtype and Knockout mice*

Accession no.

Gene name

X14206
NM_145619
BC025847
NM_027272

Mouse mRNA for poly (ADP-ribose) polymerase
Poly (ADP-ribose) polymerase family, member 3
Poly (ADP-ribose) polymerase family, member 4
Poly (ADP-ribose) polymerase family, member 8
mRNA
Mus musculus poly (ADP-ribose) polymerase
member 11 (Parp11), mRNA.
Poly (ADP-ribose) polymerase family, member 12
Poly (ADP-ribose) polymerase family, member 14
Peroxisome proliferative activated receptor,
coactivator 1 alpha
Peroxisome proliferative activated receptor,
coactivator 1 beta

NM_181402
NM_172893
BC021340
NM_008904
AK045690

* P<0.05; ns, no significant difference

FDWT

FAWT FDWT
DMH DMH

FDβ-pol
DMH

ns
ns
ns
(Parp8), -2.7

ns
ns
ns
ns

ns
1.4
ns
ns

-1.4
1.5
1.6
2.9

family, ns

ns

ns

1.5

ns
ns
gamma, ns

-1.2
ns
-1.8

ns
1.4
-1.7

1.6
3.7
1.19

gamma, ns

ns

ns

1.3

+/-
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Table XI. Summary of the effect of folate deficiency on energy sensors, glucose uptake, glycolysis, fatty
acid oxidation, mitochondrial biogenesis, fat acid synthesis, sterol synthesis, glycogen synthesis and protein
synthesis in wildtype and DMH treated wildtype and Knockout mice*
FDWT

Accession no.
NM_133781
NM_011492
NM_031869
BC043920
NM_009204
NM_133232
AK032149
BC023946
NM_008255
NM_145572

Gene name
Calcium binding protein 39
Serine/threonine kinase 11
Protein kinase, AMP-activated, beta 1
non-catalytic subunit
FK506 binding protein 12-rapamycin
associated protein 1
Solute carrier family 2 (facilitated glucose
transporter), member 4
6-phosphofructo-2-kinase/fructose-2,6biphosphatase 3
Peroxisome
proliferative
activated
receptor, gamma, coactivator 1 alpha
Acetyl-Coenzyme A carboxylase alpha
3-hydroxy-3-methylglutaryl-Coenzyme A
reductase
Glycogen synthase 2

* P<0.05; ns, no significant difference

FAWT
DMH

FDWT
DMH

FDβ-pol
DMH

-1.2

-1.2

-1.3

2.1

1.2
ns

ns
ns

ns
ns

1.2
1.2

-1.3

ns

ns

-1.8

ns

ns

ns

1.7

ns

ns

ns

2.0

ns

ns

-1.7

1.4

ns
ns

ns
ns

ns
-2.1

-1.3
-1.6

ns

ns

ns

-2.1

+/-
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Table XII. Summary of the effect of folate deficiency on cell cycle genes in wildtype and DMH treated
wildtype and Knockout mice*
FDWT

Accession no.
NM_009870
NM_009873
NM_009874
NM_007633
NM_172301
NM_016756
NM_023284
NM_175384
NM_007659
NM_013538
NM_028023
NM_026410
NM_025866
AK076422
NM_010849
NM_007670
NM_007669
NM_009875
NM_007670
NM_009876
NM_009029
U59758
NM_134092
BI646741
NM_008540
NM_019827
AK048970
NM_007691
NM_016681

Gene name
Cyclin-dependent kinase 4
Cyclin-dependent kinase 6
Cyclin-dependent kinase 7 (homolog of Xenopus MO15
cdk-activating kinase)
Cyclin E1
Cyclin B1
Cyclin-dependent kinase 2
Cell division cycle associated 1
Cell division cycle associated 2
Cell division cycle 2 homolog A (S. pombe)
Cell division cycle associated 3
Cell division cycle associated 4
Cell division cycle associated 5
Cell division cycle associated 7
Cell division cycle associated 8
Myelocytomatosis oncogene
Cyclin-dependent kinase inhibitor 2B (p15, inhibits
CDK4)
Cyclin-dependent kinase inhibitor 1A (P21)
Cyclin-dependent kinase inhibitor 1B (P27)
Cyclin-dependent kinase inhibitor 2B (p15, inhibits
CDK4)
Cyclin-dependent kinase inhibitor 1C (P57)
Retinoblastoma 1
P53-variant (p53)
Mdm2, transformed 3T3 cell double minute p53 binding
protein
MAD homolog 3 (Drosophila)
MAD homolog 4 (Drosophila)
Glycogen synthase kinase 3 beta
Ataxia telangiectasia mutated homolog (human)
Checkpoint kinase 1 homolog (S. pombe)
Mus musculus CHK2 checkpoint homolog (S. pombe)
(Chek2), mRNA.

* P<0.05; ns, no significant difference

FAWT
DMH

FDWT
DMH

FDβ-pol
DMH

ns
ns
ns

ns
2.2
ns

1.4
ns
ns

-1.6
-1.4
-1.3

ns
ns
ns
ns
1.3
ns
ns
ns
1.4
1.5
ns
1.3
-1.2

ns
1.4
1.4
1.5
1.5
ns
1.2
1.3
1.4
1.5
1.3
1.4
ns

ns
1.3
ns
1.5
ns
1.4
ns
ns
1.5
ns
1.4
1.3
ns

-1.5
-2.6
-1.8
-1.7
-2.1
-2.5
-2.4
-1.2
-1.9
-1.7
-2.3
-1.2
1.6

-1.4
-2.5
-1.3

-1.5
-3.5
ns

-1.4
-1.5
ns

1.3
1.2
1.6

-1.7
1.6
ns
1.3

-1.3
-1.2
ns
1.5

ns
ns
ns
1.4

1.4
1.2
-1.8
-1.5

ns
1.2
-1.7
ns
1.5
ns

-1.4
-1.4
-1.4
ns
1.8
1.3

-1.4
-1.5
-2.4
ns
1.7
ns

1.6
ns
1.3
-1.6
-1.6
-1.9

+/-
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Table XII. Summary of the effect of folate deficiency on colon cancer genes in wildtype and DMH treated
wildtype and Knockout mice*
FDWT

Accession no.
BI646741
NM_008540
AK036317
AK088784
NM_015732
AK039745
NM_010234
NM_010591
NM_010849
NM_016700
NM_009689

Gene name
MAD homolog 3 (Drosophila)
MAD homolog 4 (Drosophila)
V-raf-leukemia viral oncogene 1
Glycogen synthase kinase 3 beta
Axin2
Adenomatosis polyposis coli
FBJ osteosarcoma oncogene
Jun oncogene
Myelocytomatosis oncogene
Mitogen activated protein kinase 8
Baculoviral IAP repeat-containing 5

* P<0.05; ns, no significant difference

ns
1.2
ns
-1.6
1.4
-1.6
-1.6
ns
1.3
ns
ns

FAWT
DMH

-1.4
-1.4
ns
ns
ns
ns
ns
ns
ns
ns
ns

FDWT
DMH

-1.4
-1.5
-2.2
-2.4
ns
-1.3
-1.3
ns
1.3
ns
ns

FDβ-pol
DMH

1.6
ns
1.5
1.3
-1.7
1.7
1.5
1.9
-1.4
-1.4
-2.8

+/-
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Discussion
We have previously shown the consequence of β-pol heterozygosity on
the development and progression of ACF in DNA polymerase β heterozygous
knockout mice of C57BL/6 background (122), characterized formerly in our lab
(122). In these studies both wildtype and β-pol haploinsufficient mice did not
display any ACF in their colon, indicating that β-pol haploinsufficiency and
successive BER deficiency is not enough to induce ACF in mice on its own. This
suggests that β-pol is a low penetrance gene requiring some other insult in the
environment, such as an exposure to a chemical or a nutritional deficiency.
Therefore,

to

induce

ACF

formation,

we

injected

30mg/kg

i.p.

1,2-

dimethylhydrazine (DMH), a known colon and liver carcinogen, for 6 weeks. DMH
produces alkylation damage (06-meG and N7-meG) as well as oxidative
damage, damages we have shown (60) to be processed normally by the BER
pathway. As expected, β-pol haploinsufficient mice, sacrificed 6 weeks after final
DMH injection, showed a significant 67% higher level of ACF formation
(29.7+1.4) as compared to their wildtype counterparts (15.4+1.8), indicating that
+/-

β-pol

mice are more sensitive to both alkylation and oxidative damage. Noting

these changes and having previously established that β-pol haploinsufficiency
appears to mimic the effects of folate deficiency on the BER pathway, we then
proceeded to look at the effect of folate deficiency (FD) on ACF formation in the
+/-

β-pol

, for deficiency in this B vitamin has been implicated in colon

carcinogenesis. Interestingly, FD in wildtype mice subject to DMH showed a
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significant increase in ACF formation (37.6+5.2) relative to their wildtype
+/-

counterparts, however, when FD was imposed in the β-pol

, we saw a 50%

decline in ACF formation (18.3+4.1) after DMH treatment. This indicated that βpol haploinsufficiency attenuated the carcinogen-induced ACF formation when
folate was deficient. There was no significant difference in the number of
aberrant crypts per focus 12 weeks after sacrifice. When mice were
macroscopically observed 40 weeks post treatment there was an apparent
regression in the number of ACF in DMH treated mice, however, there was a
significant increase in the number of aberrant crypts per focus in FDWT mice
relative to their WT counterparts (7.63+0.4 versus 6.33+0.4, respectively),
indicating a progression of this disease. In addition, methylene blue staining of
formalin-fixed colon tissue showed defined elevation of ACF above the
surrounding mucosa in FD fed mice, while the FA mice displayed less developed
ACF, providing further evidence of advanced ACF formation. Based on the
progression of ACF, we decided to conduct proliferative and apoptotic assays to
further visualize the growth changes of these aberrations. Interestingly, TUNEL
assay results showed a significantly greater level of apoptotic activity, while BrdU
+/-

assays showed significantly more proliferation (BrdU incorporation) in FD β-pol

DMH treated colon mucosa compared to FAWT counterparts. Noting all of the
aforementioned changes in colon morphology, we wanted to determine the
impact of β-pol haploinsufficiency and FD on gene expression in colonic mucosal
tissue.
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Sequentially,

to

determine
+/-

formation and progression in β-pol

possible

mechanisms

of

reduced

ACF

, we, in our current study, decided to conduct

microarray analyses’ on FDWT, FAWT DMH treated, FDWT DMH treated and
+/-

FD β-pol

DMH treated relative to FAWT colon mucosa. The genome-wide

gene expression pattern in the colonic mucosa of these mice was investigated
using the Affymetrix G4122A, Whole Mouse Genome and G4122F, Whole
Mouse Genome.
The present data support our previous findings of β-pol haploinsufficiency
conferring a protective effect in the development of colon cancer. Firstly we
+/-

determined the reduced expression of MTHFR, DHFR and TS in FD β- pol

DMH treated colonic mucosa. In a study conducted by Tsourouflis et al., (173) in
human colon cancer primary tumor specimen, they discovered a significant
number of samples testing positive for TS, defining TS as an independent
prognostic risk factor for colon cancer. Shimoda et al., (174), in their investigation
on humans with pancreatic and biliary cancers likewise identified higher levels of
TS in cancerous than noncancerous tissues. TS is necessary for
DNA synthesis and has become therapeutic target for a number of cancers,
particularly rapidly dividing cells that make vital use of their nucleotide synthesis
machinery. Inhibition of TS results in an increase in dUTP pools, and incorporation
of uracil into DNA. BER is responsible for the removal of uracil; however, when
thymidylate is deficient and dUTP levels are elevated, uracil continually becomes
misincorporated into the DNA leading to ‘catastrophic’ BER, with subsequent
elevated levels of DSB and eventual cell death (175, 176, 177).

104
Peters et al., (178) in there study utilizing high doses of 5-fluorouracil (5-FU), a

TS inhibitor, on 5-FU-sensitive and -resistant human colon cancer cell lines
demonstrated enhanced TS inhibition, which also prevented TS induction and
increased the antitumor effect. In this study we determined a significant
+/-

reduction in gene expression of MTHFR and DHFR in FD β- pol

DMH treated

mice. Both of these enzymes catalyze reactions that require the use of energy in
the form NADPH.
Denoting the irregularity in folate metabolism, we studied the effects of βpol haploinsufficiency on the expression of DNA repair genes when DMH was
injected in a folate deficient environment. We first looked at BER for BER has the
primary role in processing the damage created by this environment. Genes
related to BER were significantly downregulated in this animal model. Due to
folate restriction there is a soaring elevation in uracil misincorporation. β-pol
haploinsufficiency would lead to deficient BER activity giving rise to SSB which
would eventually lead to DSB formation and the triggering of eventual cell death.
In addition, we see an elevation in PARP gene expression, with the exception of
+/-

PARP1 in β-pol

. PARPs are known to assist in the repair of single-strand DNA

nicks, however, if significantly elevated, PARPs deplete ATP levels. Peterman et
al., (179) using synthetic oligonucleotides, have shown a lack of short patch BER
under conditions of ATP shortage. They also report maintenance of long patch
BER through strand displacement by XRCC1 when ATP levels are reduced.
Others, in their observations, show poly(ADP-ribose) being converted to ATP by
pyrophsphorolytic cleavage using the pyrophosphate generated from dNTPs
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during DNA repair synthesis (180). In our studied we see a reduced capacity of
both short and long patch BER. Reduction in short patch repair could be
explained by β-pol haploinsufficiency, as well as, a nucleotide and ATP shortage,
whereas the altered ability for long patch repair may lie in the fact that, in addition
to aforementioned, there is a downregulation in XRCC1, as well, there is a
reduction in PARP1, a gene necessary for recruitment of BER enzymes to sites
of DNA damage.
Homologous Recombination (HR) and non-homologous end-joining
(NHEJ) are instrumental in the repair of DSB that can incur as a result of
persistent BER intermediates. Yang et al., (181) studied the effect of thymidylate
deprivation, through raltitrexed (RTX), in H-29 human colon cancer cells and
HeLa human cervical cancer cells. Their results show an induction of HR which
influences a cellular resistance to RTX. Using RTX treated cell line 9-2, which
was derived by stably transfecting GM00637 cells with pTNeo99-7, Waldman et
al., (182) demonstrated adequate NHEJ. In our study we see a reduction in a
number of HR/NHEJ related genes with β-pol haploinsufficiency, implying that
another causative effect is occurring other than thymidylate deprivation for
reduced HR/NHEJ repair capacity. We propose that in addition to lack of
thymidine, nucleotide and ATP shortage, as well as reduced PARP1 activity may
result in the deficiency of DSB repair. It should be noted that β-pol
haploinsufficiency in our damage inducible environment shows significant
downregulation in genes related to HR/NHEJ, ATM, ATR and DNA-pk
expression.
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Recent evidence has suggested that a histone code, which involves
phosphorylation, ubiquitylation, sumolation, acetylation and methylation is
involved in DNA damage detection and DNA repair. It is predicted that this code
allows for modification on a specific histone tail that can be read by other
chromatin associated proteins (183). Chromatin modification is accomplished by
a chromatin-remodeling complex, which are a family of ATP-dependent
molecular machines that participate in transcriptional regulation, DNA repair,
homologous recombination and chromatin assembly (164). The chromatinremodeling complex can destabilize histone-DNA interactions in reconstituted
nucleosomes in an ATP-dependent manner, though the exact nature of this
structural change is unknown. This code becomes important for DNA repair, for
histone modification is necessary for all repair machineries to gain access to
+/-

DNA in order to proceed (183). In this study FD β- pol

DMH treated mice show

significant downregulation in genes relative to the ATPase dependent chromatin
remodeling complex.
In addition to a potential lack of exposure of DNA in chromatin, our study
shows a distinct downregulation in H2A related gene expression. A specific
subtype of H2A, called H2afx (aka H2AX), which plays a very important role in
the cellular response to DNA damage and participates in DNA double-strand
break repair is significantly downregulated in β-pol haploinsufficiency upon
exposure to DMH in a folate deficient environment. This enzyme is normally
phosphorylated by ATM/ATR (involved in HR) or by DNA-pk (involved in NHEJ)
(183, 184, 184). These 3 aforementioned genes, as previously stated, are
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+/-

downregulated in FD β- pol

DMH treated mice. Upon phosphorylation of

H2AX, then called γ-H2AX, it co-localizes to nuclear foci at sites of DNA damage
(186). γ-H2Ax is believed to then recruit checkpoint proteins such as BRCA1,
MRE11/RAD50/NBS1 complex, MDC1 and 53BP1 to the site of DNA damage
(187). Interestingly, with the exception of MDC1, all the aforementioned genes
+/-

are significantly downregulated in FD β- pol

DMH treated mice. Hong et

al.(188), in there study utilizing WTHBF-6 cells derived from primary human
bronchial fibroblasts, demonstrated a co-localization of Mre11 to gamma-H2A.X
and ATM when cells were exposed to Hexavalent chromium, an agent that
induces DNA double strand breaks. Here we see lack of induction of ATM/ATR
or DNA-pk inferring inhibition of phosphorylation of H2AX disallowing DNA repair
to occur via HR and NHEJ.
Our current study shows a lack of expression of PARP1.

PARP1

+

catalyzes the conversion of NAD into nicotinamide and poly(ADP-ribose) and is
shown to be required for genome repair, DNA replication and the regulation of
transcription (189). Liu et al. (190), in their study using HeLa cells treated with
MNNG and ABT-888, a potent PARP inhibitor, facilitated the induction of
apoptosis without a reduction in the level of ATP. Similarly, Ghosh et al. (191),
showed PARP1 inhibition through Benzamide in HeLa cells resulted in an
induction of apoptosis under mild oxidative stress. They also demonstrate that
reduced PARP1 results in an increase in nuclear fragmentation and increased
+

caspase 3 activity along with an increase in cellular NAD levels. In addition, a
decrease in general poly(ADP-ribosyl)ation is seen. It should be noted that the
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extensive DNA damage caused overactivation of PARP1 followed by severe ATP
depletion which is hence causative of necrotic cell death (192). Interestingly, FD
+/-

β-pol

DMH treated mice show significant downregulation in Apoptosis-inducing

factor (AIR)-like mitochondrion-associated inducer of death and Endonuclease G,
genes involved in necrosis. Boulares et al. (193), using human osteosarcoma
cells show that PARP1 cleavage during apoptosis is required for both the
prevention of excessive depletion of NAD and ATP and to release of DNase1L3.
DNase1L3 is inhibited by poly(ADP-ribosyl)ation.
+/-

FD β-pol

DNase1L3 is upregulated in

DMH treated mice indicating a lack of its ribosylation and instead acts

to mediate the breakdown of DNA during apoptosis. In a study on primary
myeloid leukemic cells and myeloid leukemic cell lines which have double strand
DNA repair defects, Gaymes et al. (194) used PARP inhibitors, KU-0058948 and
PJ34, which induced cell cycle arrest and apoptosis. This study depicts a
downregulation in PARP1. It is currently unknown if this effect is either via
cellular signaling to reduce its expression or as a result of CASP3 activity.
Regardless, this reduced expression appears to enlist apoptosis. In this study,
+/-

FD β-pol

DMH treated mice show a significant upregulation in expression of

apoptotic genes. The lack of expression of necrotic genes would indicate that
+/-

the activity occurring in the mucosal cells of FD β-pol

DMH treated mice is of

low cellular energetic stress, however, not to the degree where death is induced
via necrosis.
+/-

FD β-pol

DMH treated mice show an increase in expression of cellular

energy stress sensors, including CAB39 and STK11 confirming energetic stress
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in this environment. In response to energy stress, cells activate AMPK
downstream of the tumor suppressor, STK11. We also see an increase in
expression of APRT which catalyzes the formation of AMP and inorganic
pyrophosphate from adenine and 5-phosphoribosyl-1-pyrophosphate (PRPP)
indicating an elevation in the level of AMP/ATP ratio. Interestingly, Prkab1
+/-

(AMPK), which is elevated in FD β-pol

DMH treated mice, is activated when

intracellular levels of ATP decline and intracellular levels of AMP increase (195),
the former allosterically activating Prkab1 (196). These findings seem to mimic
the effects of AMP-mimetic AICAR, which is a pharmacological target of human
cancers that suppress cancer cell growth (197). In addition to elevated energy
sensing genes there is also an increase in expression of CaMKK (CaMKK2),
another physiological activator of AMPK (198). STK11 and CaMKK are two
kinases that phosphorylate AMPK for its activation (199). Yee et al. (200), in
there study on cervical cancer cell lines reveal that, A23187, an alternative
pharmacological AMPK activator inhibits cancer cell growth through CaMKK.
Increased intracellular Ca

2+

causes an increase in CaMKK (199). Chern et al.

(201), utilizing human hepatoma Hep G2 cells, showed an overproduction of
hydrogen peroxide as a result of the oxidative stress imposed by folate deficiency
which ultimately led to cell death through apoptosis. Satu et al. (203), in their
study on rat hepatocytes demonstrate H2O2 impairment of mitochondrial
function via oxidative stress, that reduces intracellular ATP production, and in
turn opens ATP-sensitive, non-specific cation channels, leading to Ca2+ influx
which can trigger apoptosis.
treated

+/-

CaMKK is upregulated in FD β-pol

DMH
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mice and is downregulated in FD WT untreated animals. These findings would
indicate that the oxidative stress imposed by FD in β-pol haploinsufficiency would
result in increased intracellular calcium levels leading to CaMKK activation of
AMPK, as well as, the induction of apoptosis.
AMPK is known to maintain a balance between ATP production and its
+/-

consumption in all eukaryotic cells. In this current study FD β-pol

DMH treated

mice show compromised energy status thus activating catabolic pathways while
diminishing macromolecule biosynthesis, cell growth and proliferation through
AMPK. We see an increase in GLUT4 expression which induces glucose uptake,
Pfkfb3,

upregulating

glycolysis

and

Ppargc1,

implicated

in

increased

mitochondrial biogenesis. Additionally we see a decrease in Acaca expression,
indicative of a reduction in fatty acid synthesis, Hmgcr, involved in sterol
+/-

synthesis, GYS2, causing a decrease in glycogen synthesis (FD β-pol

DMH

treated mice show an upregulation of GSK3b which inhibits GYS2) and an
increase in EF2K which inhibits both protein synthesis and mTOR activity (203).
All of these findings are not significantly altered in all other animal models with
the exception of an increase in Acaca and downregulated expression of mTOR in
FD WT mice. This would indicate that β-pol haploinsufficiency subject to
prolonged FD subsequent to DMH treatment activates AMPK, switching on ATP
on ATP-generating pathways, like glycolysis, but also switches off ATPconsuming biosynthetic pathways.
In this study we demonstrate an inhibition of gene expression related to
cell growth and an upregulation in expression of cell cycle arrest genes in FD β-

111
+/-

pol

DMH treated mice. We show that β-pol haploinsufficiency 1) induces G1

and G2/M arrest; 2) downregulates cdk4/6, cdk2, ccne1, cdc2a and ccnb1
expression; and 3) upregulates gene expression of cdkn1a (p21), cdkn1b (p27),
cdkn2b (p15) and cdkn1c (p57). Autonomy of growth signals and avoidance of
cell death has been described by Hanahan et al. (204) as two of the six
necessary changes in cell physiology that dictate malignant growth. Therefore,
our animal model has the ability to induce apoptosis and inhibit cell cycle
progression in colon cancer, and as such these mechanisms may potentially be
utilized in the chemoprevention of colon cancer.
Lastly, we looked at expression of genes relative to the colorectal cancer
+/-

pathway. Interestingly, FD β-pol

DMH treated mice show a reduction of

expression of genes downstream of this pathway. Namely, there is a reduction in
survivin which is an antiapoptotic gene, as well as, Myc which encourages
proliferation. Expression of these are either unchanged or show opposite
+/-

correlation to FD β-pol

DMH treated in all other animals tested.

In January of 1998, the United States imposed mandatory fortification of
enriched cereal-grain products with folic acid to help prevent pregnancies
affected by a neural tube defect (NTD) and potentially other malformations in
their babies like cleft palate and lip and cardiac defects. Previous research
suggested that folate deficiency appeared to play an important pathogenic role in
the development of many disease states beyond NTDs including cardiovascular
disease, Alzheimer’s disease and cancer (205). Due to the fact that the
prevention effort targeted preconceptional women of child-bearing age, the
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mandate exposed the entire population to this enrichment. This seemed feasible
for folate is by and large regarded as safe and advantageous for disease
prevention. The premise of this endeavor is working for the data from the 1999 to
2000 National Health and Nutrition Examination Survey (NHANES) revealed a
considerable increase in median serum folate concentrations in nonpregnant
women of childbearing age compared to 1988 to 1994. Our current findings
suggest that this massive effort to eradicate folate deficiency maybe detrimental
under certain conditions, particularly certain cancers. Here we show that a
deficiency in this B-vitamin may confer a protective effect in colon
carcinogenesis. These findings seem sensible for if one considers the needs of
rapidly dividing preneoplastic lesions like the ACF, folate would supply the
necessary environment, principally to repair machinery, which ultimately may
inflict more damage due to erroneous repair. Our findings imply that folate
deficiency is needed in conjunction with a BER deficiency in order to reduce
repair of damage created by this vitamin deficit, not only by BER but as well,
repair by other pathways.
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Summary and Future Directions
Folate has emerged as an important nutritional element in the
pathogenesis of several malignancies, including cancers of the colorectum, lung,
pancreas, esophagus, stomach, cervix, and breast, as well as neuroblastoma
and leukemia. Studies have collectively implied an inverse association between
both dietary and serum folate and the risk of malignancy (1, 2); the most
evidence relating to colorectal cancer (CRC) (3, 4). This information would
appear, in light of these current studies, to be counterintuitive. Folate is
especially important during periods of rapid cell division and growth such as seen
in neoplastic cells. In addition, folate deficiency reduces intracellular nucleotide
precursor pools; increasing uracil misincorporation and DNA strand breaks (5, 6)
measures that would seem beneficial for the suppression of cancer cells.
Here we show that folate deficiency not only suppresses onset and
progression of ACF but in addition appears to reduce the level of cellular energy
such that cells do not have the power to maintain viability. This study
demonstrates an inhibition of nucleotide synthesis through an interruption in the
folate pathway, chromatin condensation, an arrest in cell cycle progression and
cellular signaling to energy sensors when β-pol is haploinsufficient in a folate
deficient environment. In addition, we show reduced DNA repair and increased
apoptotic activity. We propose that the oxidative and alkylation damage imposed
by folate and DMH treatment resulted in the recruitment of PARPs to the sites of
DNA damage. With a lack of β-pol, damage created would continually signal for
repair, bringing in an abundance of PARP. This in turn would result in a
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reduction in the mitochondrial membrane potential and ATP depletion leading to
energy failure and cell death. PARP-1 activation leads to ATP depletion and
necrosis (205, 206). Here we propose that as a result of PARP1 abundance, the
apoptotic pathway is signaled leading to activation of caspases which cleave
PARP1 and thereby preserve ATP. As seen in this current study, PARP1 is
downregulated, switching the mode of death from necrosis to apoptosis, as seen
by lack of response by necrotic enzymes but a significant increase in apoptotic
activity. Here we suggest that after immediate exposure to DMH, PARP1 is
recruited to sites of DMH damage, however, a deficient BER leads to elevated
PARP activity. This elevation creates cellular energetic stress, signaling
apoptosis or necrotic cell death. Having theorized this, PARP levels immediately
after final injection such be ascertained. Six weeks after the final DMH injection,
however, PARP1 activity is reduced leading to apoptosis signifying the level of
ATP depletion governs the mode of cell death. Similar findings were reported by
Ha et al. (206) in their study using fibroblasts of PARP

−/−

animals after exposure

to either MNNG or H2O2. Other modes of DNA repair are reduced possibly
secondary to apoptotic cell signaling, lack of induction of PARP activity, reduced
cellular energy levels to mediate repair and by the lack of sufficient purine and
pyrimidine synthesis. Lastly, current chemotherapeutic regimens for all causes of
colon cancer utilize the same therapeutic agents; oxaliplatin, an alkylating agent
proposed to prevent DNA synthesis, 5-fluorouracil (5-FU), an inhibitor of
thymidylate synthase, and leucovorin, which enhances the binding of 5-FU in the
cell while providing a source of folic acid for normal cells. While the premise is
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understandable to some degree, questions arise regarding 5FU in the cancer cell
and the continuance of ‘catastrophic’ repair by sufficientBER machinery. Thus,
our findings appear to have both therapeutic and protective implications against
the development and progression of colon cancer by means of an alteration in
micronutrients when β-pol variants/polymorphisms exist.
Future Directions
Having elucidated the potential mechanism behind colon cancer
prevention, future studies would include a repeat of experimental procedures on
mice sacrificed immediately after final DMH injection and after approximately 40
weeks to denote significant changes that occurs at these times as compared to
our current 6 week after final injection sacrifice. This would assist in determining
cellular performance immediately after exposure to and after an extensive time
period without DMH. Studies should also be conducted on both
ACF and normal adjacent tissue extracted through laser micro-dissection to
delineate if there is a distinction in these tissues with respect to the key findings
of our current study. We propose that ACF have greater metabolic needs than
+/-

normal tissue. FD β-pol

DMH treated mice would have such a high level of

metabolic stress that energy levels become so depleted that apoptosis would
ensue. In contrast, with efficient BER, PARP levels would remain stable, allowing
for repair and thus no lack ATP levels accelerating mutational frequency. As well,
PARP1 cleavage should be assessed, for high levels of this enzyme without BER
would cause severe cellular energy depletion and signal for its cleavage via
caspases. In addition, it seems relevant to test the effects of
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caloric restriction (CR) in β-pol haploinsufficiency when subject to DMH, for
research has shown CR to increases life expectancy but as well, it would help
delineate if what is found in our current study is a result of folate in a β-pol
deficient environment or is it that folate depletes cellular energetic stores through
the various aforementioned mechanisms and that CR could in fact mimic these
findings. As well, it would be interesting to test the effects of β-pol
haploinsufficiency in both the APC min mouse and MMR deficient mouse models
fed a folate deficient diet, to test our current findings of protection when BER is
deficient.
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The data presented in this research is central to establishing the role that
the base excision repair pathway (BER) plays in the development and
progression of colon cancer when dietary folate is deficient. Both cellular folate
restriction and BER deficiencies have been shown to result in the accumulation
of endogenous damage and lesions that could eventually develop into
carcinogenesis. In this study, a dietary folate deficiency (FD) resulted in a
significant increase in aberrant crypt foci (ACF) formation and triggered liver
tumorogenesis in wildtype (WT) animals, as did a BER deficiency in DNA
+/-

polymerase β haploinsufficient (β-pol

) mice exposed to 1, 2-dimethylhydrazine

(DMH), a known colon and liver carcinogen. We combined both folate restriction
and a BER deficiency to determine the fate of colon tissue after exposure to
DMH. Of interest, we show that this model supports a protection against colon
carcinogenesis. FD attenuated onset and progression of ACF and prevented liver
tumorigenesis in β-pol haploinsufficient mice. Analysis of the data suggests

148
that the mechanism by which this phenomenon occurs appears to be through an
elevation in DNA damage that signals recruitment of PARP enzymes to the site
of damage, however, with a deficiency in BER, PARP function in DNA repair is
futile leading to a depletion of cellular energetic levels. This energetic stress is
sensed by cell death machinery and as such apoptosis is invoked.
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